AC Immune (NASDAQ: ACIU) posts 2025 loss but flags key 2026 trial milestones

Q: How did AC Immune (ACIU) perform financially in 2025?

AC Immune generated CHF 3.6 million in 2025 contract revenue, down from CHF 27.3 million in 2024. The company reported a net loss of CHF 70.4 million versus CHF 50.9 million the prior year, with basic and diluted loss per share of CHF 0.70 .

Q: What is AC Immune’s cash position and liquidity at year-end 2025?

At December 31, 2025, AC Immune held CHF 26.8 million in cash and cash equivalents and CHF 64.6 million in short-term financial assets. Management concluded it can meet obligations for at least 12 months and prepared the financial statements on a going-concern basis, while acknowledging typical clinical-stage funding risks.

Q: What did AC Immune report about ACI-7104 in Parkinson’s disease?

AC Immune highlighted “ exceptional interim data ” from the VacSYn Phase 2 trial of ACI-7104, its wholly owned anti‑α‑synuclein active immunotherapy. Management stated that evidence suggests ACI-7104 appears to slow progression in early Parkinson’s disease, supporting the concept of disease‑modifying active immunotherapies.

Q: What is the large intangible asset on AC Immune’s balance sheet?

AC Immune carries a CHF 50.4 million acquired in‑process research and development (IPR&D) asset, a clinically validated active immunotherapy candidate for Parkinson’s disease. The asset is not yet amortized, is tested annually for impairment under IAS 36, and was assessed as not impaired at December 31, 2025.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

AC Immune reported full-year 2025 results, highlighting pipeline progress alongside a wider loss. Contract revenue fell to CHF 3.6m from CHF 27.3m, mainly as prior Janssen milestones rolled off, while the net loss widened to CHF 70.4m with a basic and diluted loss per share of CHF 0.70.

Cash and cash equivalents were CHF 26.8m and short-term financial assets CHF 64.6m as of December 31, 2025, and management prepared the accounts on a going-concern basis. The company emphasized positive interim VacSYn Phase 2 data for ACI-7104 in early Parkinson’s disease, a Phase 1 NLRP3 inhibitor (ACI-19764), and a sharpened pipeline focus supported by 2025 restructuring.

Insights

Sharpened pipeline and solid cash base offset a steep revenue drop and wider 2025 loss.

AC Immune shifted from milestone-driven revenue to a leaner, R&D-focused model in 2025. Contract revenue declined to CHF 3.6m, while operating expenses remained substantial at CHF 72.9m, driving a net loss of CHF 70.4m.

Liquidity remains important: cash and cash equivalents of CHF 26.8m plus short-term financial assets of CHF 64.6m underpinned the going-concern assessment for at least 12 months. A large IPR&D intangible of CHF 50.4m was tested and not impaired, but depends on successful Parkinson’s development.

Pipeline news is a key offset to financial pressure. Management highlighted “exceptional” interim VacSYn data for ACI-7104 in early Parkinson’s, a Phase 1 NLRP3 inhibitor, and multiple 2026 milestones, including VacSYn Phase 2 Part 1 data and ACI-24 and Morphomer readouts. Restructuring costs of CHF 0.5m and an associated pension curtailment gain signal tighter cost control.

03/13/2026 - 07:02 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March, 2026

Commission file number: 001-37891

AC IMMUNE SA

(Exact Name of Registrant as Specified in Its Charter)

EPFL Innovation Park

Building B

1015 Lausanne, Switzerland

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX



Exhibit Number		Description
99.1		Press Release dated March 13, 2026
99.2		2025 IFRS Consolidated Financial Statements
99.3		2025 Statutory Annual Report
99.4		2025 Compensation Report

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	AC IMMUNE SA

	By:	/s/ Andrea Pfeifer
		Name: Andrea Pfeifer
		Title: Chief Executive Officer


	By:	/s/ Christopher Roberts
		Name: Christopher Roberts
		Title: Chief Financial Officer

Date: March 13, 2026

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

●

Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson’s disease

●

NLRP3 inhibitor ACI-19764 Phase 1 trial initiated with first participants dosed

●

Approaching multiple value-inflection points, including interim results of the AD3 cohort in the Phase 2 ABATE trial of ACI-24 in Alzheimer’s disease in H1 2026, and full 24-month data from Part 1 of the Phase 2 VacSYn trial of ACI-7104 in Q3 2026

●

Cash resources of CHF 91.4 million as of December 31, 2025, provide funding to the end of Q3 2027 before any potential milestone payments

Lausanne, Switzerland, March 13, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the full year ended December 31, 2025, and provided a corporate update.

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress towards delivering precision prevention of neurodegenerative diseases in 2025, exemplified by the exceptional interim data from the VacSYn trial of ACI-7104, our wholly-owned active immunotherapy targeting α-synuclein. Evidence that ACI-7104 appears to slow the rate of progression in early Parkinson’s disease (PD) further demonstrates the potential for active immunotherapies as disease-modifying treatments with the potential to slow or prevent neuronal damage.”

“Our novel Morphomer® small-molecule therapeutics complement these programs by targeting intracellular mechanisms, enabling intervention at the earliest stages of disease. ACI-19764, a brain-penetrant NLRP3 inhibitor with potential to treat numerous diseases both within and beyond neurodegeneration, is now in a Phase 1 trial.”

Full Year 2025 and Subsequent Highlights:

ACI-7104 anti-α-synuclein active immunotherapy

●

Reported positive interim safety and efficacy results from Part 1 of the Phase 2 VacSYn trial of our wholly-owned anti-α-synuclein active immunotherapy ACI-7104 in early PD.

●

Results suggest, for the first time, that targeting underlying α-synuclein pathology with an active immunotherapy may slow the rate of progression of Parkinson’s disease.

●

These results could translate into a shift from treating symptoms toward true disease modification in PD

●

Clear safety profile with no clinically relevant safety issues reported to date

●

Targets met for immunogenicity (100% responder rate), pharmacodynamic effect, target engagement and clinical assessments

●

Final data from Part 1 of the study expected in mid-2026.

Morphomer-Tau small molecule program

●

Progressed the Morphomer small molecule Tau aggregation inhibitors for the potential treatment of Alzheimer’s disease (AD) and other neurodegenerative diseases.

●

Investigational New Drug (IND)-enabling studies are expected to begin in H1 2026.

NLRP3 inhibitor, ACI-19764, small molecule program

●

Dosed the first participants in a Phase 1 clinical trial of ACI-19764, a brain-penetrant small molecule targeting the NLRP3 inflammasome (NCT07463196).

●

Our NLRP3 inhibitors have potential to intervene at the earliest stages of disease in neurodegenerative conditions, including AD, PD, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

●

Potential additional indications include inflammatory disorders (e.g., multiple sclerosis, inflammatory bowel disease, gout), cancer, cardiovascular disease, metabolic disorders (e.g., Type 2 diabetes, obesity), skin inflammatory diseases (e.g. hidradenitis suppurativa) and rare genetic syndromes of autoimmunity such as Cryopyrin-associated periodic syndromes (CAPS).

●

ACI-19764, an orally available, brain-penetrant NLRP3 inhibitor is a major addition to AC Immune’s growing intracellular targeting pipeline.

Sharpened Pipeline Focus with Operational Efficiencies Extending Cash Runway

●

Following a strategic review by executive management, sharpened investment on our most important assets.

●

These include the three clinical-stage active immunotherapy programs ACI-7104, ACI-24 and ACI-35, the latter two of which are in ongoing pharma collaborations, and promising small molecule programs targeting NLRP3, Tau and α-synuclein.

●

The Company reduced its workforce by around 30% and extended its cash for operations to the end of Q3 2027.

AC Immune research results published in peer-reviewed journals and presented at conferences:

●

Clinical results from the completed Phase 1b/2a trial of active immunotherapy ACI-35 (JNJ-2056) partnered with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, in eBioMedicine.

●Preclinical research demonstrating the in vivo activity of a vectorized (AAV9) anti-TDP-43 monoclonal antibody in a model of ALS/FTD, in Molecular Therapy.

●First-in-class positron emission tomography (PET) tracers for imaging TDP-43 pathology in the brain, including ACI-19626, that could enable a precision medicine approach to neurodegenerative diseases which are currently difficult to diagnose, in Nature Communications.

●Featured the company’s therapeutic and diagnostic programs in presentations at AD/PD™ 2025 where we also hosted an industry symposium highlighting the company’s leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseases.

Appointed Prof. Catherine Mummery, a renowned neurologist and expert in dementia clinical trials, as Chair of Ac Immune’s Clinical Advisory Board (CAB).

Anticipated 2026 Milestones


Program	Milestone	Expected in
ACI-7104 anti-α-synuclein active immunotherapy	Final data from Part 1 of the Phase 2 VacSYn trial in PD expected in mid-2026	H2 2026
ACI-24 anti-Abeta active immunotherapy	Interim results from ABATE Phase 2 trial after reaching 12-month treatment timepoint in the AD3 cohort	H1 2026
ACI-19764 NLRP3 inhibitor	Results from Phase 1 trial in healthy volunteers	H2 2026
Morphomer-Tau aggregation inhibitors	Lead declaration and initiation of IND-enabling studies	H1 2026
Morphomer α-synuclein aggregation inhibitor	Lead declaration	H1 2026

Analysis of Financial Statements for the Full Year Ended December 31, 2025

●

Cash Position: The Company had total cash resources of CHF 91.4 million as of December 31, 2025, compared to total cash resources of CHF 165.5 million as of December 31, 2024. The Company’s cash balance provides sufficient capital resources into Q3 2027, assuming no other milestones.

●

Contract Revenues: The Company recorded CHF 3.6 million in contract revenues for the year ended December 31, 2025, compared with CHF 27.3 million in the prior year. For the year ended December 31, 2025, our contract revenues of CHF 3.6 million were related to the efforts made under the agreement with Takeda for development, CMC, and regulatory activities. The decrease compared to the prior year relates to the recognition of the second ReTain-related milestone payment of CHF 24.6 million under the agreement with Janssen in 2024.

●

R&D Expenditures: R&D expense decreased by CHF 6.1 million for the year ended December 31, 2025 to CHF 56.4 million, predominantly due to:

Discovery and preclinical expenses: Decrease of CHF 1.6 million, primarily due to the completion of certain pre-clinical studies and our strategic focus on advancing clinical-stage programs.

Clinical expenses: Decrease of CHF 4.4 million, primarily due to lower costs related to manufacturing activities for our Phase 2 VacSYn study evaluating ACI-7104 in early PD and certain non-recurring manufacturing costs in 2024. These changes were offset by increased costs associated with our NLRP3 inhibitor program, which entered clinical development in 2026, and higher costs associated with our PET Tracer programs.

Salary- and benefit-related costs: Decrease of CHF 0.7 million, primarily due to decreased share-based compensation in the current year.

●

G&A Expenditures: G&A expenses decreased by CHF 1.1 million for the year ended December 31, 2025, to CHF 16.1 million. This decrease is primarily due to legal fees in 2024 which did not recur.

●

Restructuring Expenditures: Expenses recognized as a result of the restructuring were CHF 0.5 million compared to nil for the year ended 2024. These expenses include CHF 2.1 million of termination benefits, offset by a CHF 1.8

million gain on curtailment in the defined benefit pension liability. The remaining balance pertains to other non-cash activities within share-based compensation.

●

Financial Result: Net finance result was a CHF 1.1 million loss for the year ended December 31, 2025, compared with a CHF 1.5 million gain in 2024. This was due to lower interest received on net investments in short-term financial assets and foreign exchange differences caused by foreign currencies depreciating against CHF, predominantly the U.S. Dollar.

●

IFRS Loss for the Period: The Company reported a net loss after taxes of CHF 70.5 million for the year ended December 31, 2025, compared with a net loss of CHF 50.9 million for the prior year.

2026 Financial Guidance

●

For the full year 2026, the Company expects its total cash expenditure to be in the range of CHF 55-65 million. The Company defines total cash expenditure as operating expenditure adjusted to include capital expenditure and offset by significant non-cash items (including share-based compensation and depreciation expenses).

About AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.

SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CA, CN, CH, EU, GB, JP, KR, NO, RU and SG.

The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.

For further information, please contact:


SVP, Investor Relations & Corporate Communications Gary Waanders, Ph.D., MBA AC Immune Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com
International Media Chris Maggos Cohesion Bureau Phone: +41 79 367 6254 Email: chris.maggos@cohesionbureau.com

Forward looking statements

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

AC Immune SA

Consolidated Balance Sheets (Unaudited)

(In CHF thousands)


			As of
			December 31,
			2025		2024
Assets
Non-current assets
Property, plant and equipment			1,989		2,651
Right-of-use assets			4,540		5,437
Intangible asset			50,416		50,416
Long-term financial assets			584		415
Total non-current assets			57,529		58,919

Current assets
Prepaid expenses			3,972		4,302
Accrued income			360		1,099
Other current receivables			978		1,104
Short-term financial assets			64,617		129,214
Cash and cash equivalents			26,795		36,275
Total current assets			96,722		171,994
Total assets			154,251		230,913

Shareholders' equity and liabilities

Shareholders’ equity
Share capital			2,253		2,226
Share premium			481,863		478,506
Treasury shares			(218)		(218)
Currency translation differences			7		(5)
Accumulated losses			(439,021)		(368,239)
Total shareholders’ equity			44,884		112,270

Non-current liabilities
Long-term deferred contract revenue			2,339		4,560
Long-term lease liabilities			3,689		4,401
Net employee defined benefit liabilities			8,646		8,844
Total non-current liabilities			14,674		17,805

Current liabilities
Trade and other payables			2,068		2,658
Accrued expenses			8,067		12,098
Short-term deferred contract revenue			83,706		85,056
Short-term lease liabilities			852		1,026
Total current liabilities			94,693		100,838
Total liabilities			109,367		118,643
Total shareholders’ equity and liabilities			154,251		230,913

Consolidated Statements of Income/(Loss) (unaudited)

(In CHF thousands, except for per-share data)


			For the Year Ended
			December 31,
			2025		2024		2023
Revenue
Contract revenue			3,573		27,309		14,801
Total revenue			3,573		27,309		14,801

Operating expenses
Research & development expenses			(56,436)		(62,570)		(54,606)
General & administrative expenses			(16,094)		(17,259)		(15,305)
Other operating income/(expense), net			94		142		1,486
Restructuring expenses, net			(455)		—		—
Total operating expenses			(72,891)		(79,687)		(68,425)
Operating loss			(69,318)		(52,378)		(53,624)

Financial income			1,865		3,196		1,044
Financial expense			(191)		(133)		(176)
Exchange differences			(2,803)		(1,598)		(1,467)
Finance result, net			(1,129)		1,465		(599)

Loss before tax			(70,447)		(50,913)		(54,223)
Income tax expense			—		(3)		(10)
Loss for the period			(70,447)		(50,916)		(54,233)

Loss per share:
Basic and diluted loss for the period attributable to equity holders			(0.70)		(0.51)		(0.64)

Consolidated Statements of Comprehensive Income/(Loss) (unaudited)

(In CHF thousands)


	For the Year Ended
	December 31,
	2025	2024	2023
Loss for the period	(70,447)	(50,916)	(54,233)
Items that may be reclassified to income or loss in subsequent periods (net of tax):
Currency translation differences	12	46	(61)
Items that will not to be reclassified to income or loss in subsequent periods (net of tax):
Remeasurement gains/(losses) on defined-benefit plans (net of tax)	(1,353)	(3,084)	(1,669)
Other comprehensive income/(loss)	(1,341)	(3,038)	(1,730)
Total comprehensive loss, net of tax	(71,788)	(53,954)	(55,963)

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Audited consolidated financial statements — AC IMMUNE SA


Report of the statutory auditor	2
Consolidated Balance Sheets as of December 31, 2025 and 2024	8
Consolidated Statements of Income/(Loss) and Consolidated Statements of Comprehensive Income/(Loss) for the fiscal years ended December 31, 2025, 2024 and 2023	9
Consolidated Statements of Changes in Equity for the fiscal years ended December 31, 2025, 2024 and 2023	10
Consolidated Statements of Cash Flows for the fiscal years ended December 31, 2025, 2024 and 2023	11
Notes to the Consolidated Financial Statements	12

Report of the statutory auditor to the General Meeting of AC Immune SA, Ecublens

Report on the audit of the consolidated financial statements

Opinion

We have audited the consolidated financial statements of AC Immune SA and its subsidiary (the Group), which comprise the consolidated balance sheet as at December 31, 2025, and the consolidated statement of income/(loss), the consolidated statement of comprehensive income/(loss), the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including material accounting policy information.

In our opinion, the accompanying consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at December 31, 2025 and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with IFRS Accounting Standards and comply with Swiss law.

Basis for opinion

We conducted our audit in accordance with Swiss law, International Standards on Auditing (ISA) and Swiss Standards on Auditing (SA-CH). Our responsibilities under those provisions and standards are further described in the 'Auditor’s responsibilities for the audit of the consolidated financial statements' section of our report. We are independent of the Group in accordance with the provisions of Swiss law and the requirements of the Swiss audit profession that are relevant to audits of the financial statements of public interest entities, as well as the International Code of Ethics for Professional Accountants (including International Independence Standards) issued by the International Ethics Standards Board for Accountants (IESBA Code), as applicable to audits of financial statements of public interest entities. We have also fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Our audit approach

Overview

Overall group materiality: CHF 2,900 thousand

The entities addressed by our full scope audit work contribute to 99% of the Group’s total assets.

As key audit matter the following area of focus has been identified:

Intangible asset - valuation

Materiality

The scope of our audit was influenced by our application of materiality. Our audit opinion aims to provide reasonable assurance that the consolidated financial statements are free from material misstatement. Misstatements may arise due to fraud or error. They are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the consolidated financial statements.

Based on our professional judgement, we determined certain quantitative thresholds for materiality, including the overall Group materiality for the consolidated financial statements as a whole as set out in the table below. These, together with qualitative considerations, helped us to determine the scope of our audit and the nature, timing and extent of our audit procedures and to evaluate the effect of misstatements, both individually and in aggregate, on the consolidated financial statements as a whole.


Overall group materiality	CHF 2,900 thousand

Benchmark applied	3 years average loss before tax

Rationale for the materiality benchmark applied	Based on our analysis and professional judgement we determined that the average of 3 years loss before tax is the most appropriate benchmark. We chose the average of 3 years of loss before tax because it is the benchmark against which the performance of the Group is most commonly measured, and it is a generally accepted benchmark. In addition, in our view, the selected materiality threshold is aligned with investors and Audit & Finance Committee expectations.

We agreed with the Audit & Finance Committee that we would report to them misstatements above CHF 290 thousand identified during our audit as well as any misstatements below that amount which, in our view, warranted reporting for qualitative reasons.

Audit scope

We designed our audit by determining materiality and assessing the risks of material misstatement in the consolidated financial statements. In particular, we considered where subjective judgements were made; for example, in respect of significant accounting estimates that involved making assumptions and considering future events that are inherently uncertain. As in all of our audits, we also addressed the risk of management override of internal controls, including among other matters consideration of whether there was evidence of bias that represented a risk of material misstatement due to fraud.

We tailored the scope of our audit in order to perform sufficient work to enable us to provide an opinion on the consolidated financial statements as a whole, taking into account the structure of the Group, the accounting processes and controls, and the industry in which the Group operates.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Intangible asset - valuation



Key audit matter	How our audit addressed the key audit matter

As described in Note 6 to the consolidated financial statements, the Company has CHF 50.4 million of an in-process research and development (IPR&D) intangible asset as of December 31, 2025. The asset is not yet ready for use until the asset obtains market approval. Therefore, in accordance with IAS 36 ‘Impairment of asset’, the IPR&D asset is reviewed at least annually for impairment by assessing the fair value less costs to sell (recoverable amount) and comparing this to the carrying value of the asset. The significant assumptions used in the model include anticipated research and development costs, anticipated costs of goods and sales and marketing expenditures, probability of achieving clinical and regulatory development milestones in accordance with certain industry benchmarks, target indication prevalence and incidence rates, anticipated market share, general commercialization expectations such as	Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management’s valuation of the intangible asset. These procedures also included, among others, (i) testing management’s process for developing the fair value estimate; (ii) evaluating the appropriateness of the discounted cash flow model; (iii) testing the completeness and accuracy of underlying data used in the model; and (iv) evaluating the reasonableness of the significant assumptions used by management related anticipated research and development costs, anticipated costs of goods and sales and marketing expenditures, probability of achieving clinical and regulatory development milestones in accordance with certain industry benchmarks, target

anticipated pricing and uptake, expected patent life and market exclusivity periods, and the discount rate used to discount future cash flows. The Company’s valuation model calculates the risk-adjusted, net cash flows through the period of market exclusivity across target sales regions.

The principal considerations for our determination that performing procedures relating to the intangible asset – valuation is a key audit matter are (i) the significant judgment by management when determining the value of the intangible asset; (ii) a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating the audit evidence obtained related to the valuation of the intangible asset and management’s assumptions related to anticipated research and development costs, anticipated costs of goods and sales and marketing expenditures, probability of achieving clinical and regulatory development milestones in accordance with certain industry benchmarks, target indication prevalence and incidence rates, anticipated market share, general commercialization expectations such as anticipated pricing and uptake, expected patent life and market exclusivity periods, and the discount rate used to discount future cash flows; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.

indication prevalence and incidence rates, anticipated market share, general commercialization expectations such as anticipated pricing and uptake, expected patent life and market exclusivity periods, and the discount rate. Evaluating management’s assumptions related to anticipated research and development costs, anticipated costs of goods and sales and marketing expenditures, probability of achieving clinical and regulatory development milestones in accordance with certain industry benchmarks, target indication prevalence and incidence rates, anticipated market share, general commercialization expectations such as anticipated pricing and uptake, expected patent life and market exclusivity periods, involved evaluating whether the assumptions used by management were reasonable considering (i) the consistency with market and industry data; and (ii) whether these assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in the evaluation of the Company’s discounted cash flow model and the discount rate assumption.

Other information

The Board of Directors is responsible for the other information. The other information comprises the information included in the annual report, but does not include the financial statements, the consolidated financial statements, the compensation report and our auditor’s reports thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Board of Directors’ responsibilities for the consolidated financial statements

The Board of Directors is responsible for the preparation of consolidated financial statements, that give a true and fair view in accordance with IFRS Accounting Standards and the provisions of Swiss law, and for such internal control as the Board of Directors determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the Board of Directors is responsible for assessing the Group’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the consolidated financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Swiss law, ISA and SA-CH will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with Swiss law, ISA and SA-CH, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

●

Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

●	Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group’s internal control.

●	Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made.

●

Conclude on the appropriateness of the Board of Directors’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify

our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Group to cease to continue as a going concern.

●	Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

●

Plan and perform the group audit to obtain sufficient appropriate audit evidence regarding the financial information of the entities or business units within the Group as a basis for forming an opinion on the consolidated financial statements. We are responsible for the direction, supervision and review of the audit work performed for purposes of the group audit. We remain solely responsible for our audit opinion.

We communicate with the Board of Directors or its relevant committee regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Board of Directors or its relevant committee with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them regarding all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with the Board of Directors or its relevant committee, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor’s report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other legal and regulatory requirements

In accordance with article 728a para. 1 item 3 CO and PS-CH 890, we confirm the existence of an internal control system that has been designed, pursuant to the instructions of the Board of Directors, for the preparation of the consolidated financial statements.

We recommend that the consolidated financial statements submitted to you be approved.

PricewaterhouseCoopers SA


/s/ Alex Fuhrer	/s/ Thomas Kohler
Licensed audit expert	Licensed audit expert
Auditor in charge

Lausanne, March 13, 2026

Consolidated Financial Statements (IFRS Accounting Standards)

AC Immune SA

Consolidated Balance Sheets

(In CHF thousands)


				As of
				December 31,
		Note		2025		2024
Assets
Non-current assets
Property, plant and equipment		4		1,989		2,651
Right-of-use assets		5		4,540		5,437
Intangible asset		6		50,416		50,416
Long-term financial assets		5		584		415
Total non-current assets				57,529		58,919

Current assets
Prepaid expenses		8		3,972		4,302
Accrued income		8/13		360		1,099
Other current receivables		10		978		1,104
Short-term financial assets		7		64,617		129,214
Cash and cash equivalents		7		26,795		36,275
Total current assets				96,722		171,994
Total assets				154,251		230,913

Shareholders' equity and liabilities

Shareholders’ equity
Share capital		11		2,253		2,226
Share premium		11		481,863		478,506
Treasury shares		11		(218)		(218)
Currency translation differences				7		(5)
Accumulated losses				(439,021)		(368,239)
Total shareholders’ equity				44,884		112,270

Non-current liabilities
Long-term deferred contract revenue		13		2,339		4,560
Long-term lease liabilities		5		3,689		4,401
Net employee defined benefit liabilities		17		8,646		8,844
Total non-current liabilities				14,674		17,805

Current liabilities
Trade and other payables		12		2,068		2,658
Accrued expenses		9/12		8,067		12,098
Short-term deferred contract revenue		13		83,706		85,056
Short-term lease liabilities		5		852		1,026
Total current liabilities				94,693		100,838
Total liabilities				109,367		118,643
Total shareholders’ equity and liabilities				154,251		230,913

The accompanying notes are an integral part of these consolidated financial statements.

AC Immune SA

Consolidated Statements of Income/(Loss)

(In CHF thousands, except for per-share data)


				For the Year Ended
				December 31,
		Note		2025		2024		2023
Revenue
Contract revenue		13		3,573		27,309		14,801
Total revenue				3,573		27,309		14,801

Operating expenses
Research & development expenses		14		(56,436)		(62,570)		(54,606)
General & administrative expenses		14		(16,094)		(17,259)		(15,305)
Other operating income/(expense), net		13.2		94		142		1,486
Restructuring expenses, net		9		(455)		—		—
Total operating expenses				(72,891)		(79,687)		(68,425)
Operating loss				(69,318)		(52,378)		(53,624)

Financial income		14		1,865		3,196		1,044
Financial expense		14		(191)		(133)		(176)
Exchange differences		14		(2,803)		(1,598)		(1,467)
Finance result, net				(1,129)		1,465		(599)

Loss before tax				(70,447)		(50,913)		(54,223)
Income tax expense		16		—		(3)		(10)
Loss for the period				(70,447)		(50,916)		(54,233)

Loss per share:
Basic and diluted loss for the period attributable to equity holders		20		(0.70)		(0.51)		(0.64)

Consolidated Statements of Comprehensive Income/(Loss)

(In CHF thousands)


		For the Year Ended
		December 31,
	Note	2025	2024	2023
Loss for the period		(70,447)	(50,916)	(54,233)
Items that may be reclassified to income or loss in subsequent periods (net of tax):
Currency translation differences		12	46	(61)
Items that will not to be reclassified to income or loss in subsequent periods (net of tax):
Remeasurement gains/(losses) on defined-benefit plans (net of tax)	17	(1,353)	(3,084)	(1,669)
Other comprehensive income/(loss)		(1,341)	(3,038)	(1,730)
Total comprehensive loss, net of tax		(71,788)	(53,954)	(55,963)

The accompanying notes are an integral part of these consolidated financial statements.

AC Immune SA

Consolidated Statements of Changes in Equity

(In CHF thousands)


											Currency
				Share		Share		Treasury		Accumulated	translation
		Note		capital		premium		shares		losses	differences		Total
Balance as of January 1, 2023				1,797		431,323		(124)		(264,015)	10		168,991
Loss for the period				—		—		—		(54,233)	—		(54,233)
Other comprehensive loss		17		—		—		—		(1,669)	(61)		(1,730)
Total comprehensive loss				—		—		—		(55,902)	(61)		(55,963)

Share-based payments		18		—		—		—		4,365	—		4,365
Proceeds from public offerings, net of underwriting fees, transaction costs and stamp duty		11		286		40,249		—		—	—		40,535
Proceeds from sale of treasury shares in public offerings, net of underwriting fees and transaction costs		11		—		2,631		19		—	—		2,650
Issuance of shares, net of transaction costs:
Restricted share awards		18		5		645		—		(645)	—		5
Exercise of options		18		1		59		—		—	—		60
Balance as of December 31, 2023				2,089		474,907		(105)		(316,197)	(51)		160,643


											Currency
				Share		Share		Treasury		Accumulated	translation
		Note		capital		premium		shares		losses	differences		Total
Balance as of January 1, 2024				2,089		474,907		(105)		(316,197)	(51)		160,643
Loss for the period				—		—		—		(50,916)	—		(50,916)
Other comprehensive loss		17		—		—		—		(3,084)	46		(3,038)
Total comprehensive loss				—		—		—		(54,000)	46		(53,954)

Share-based payments		18		—		—		—		5,470	—		5,470
Proceeds from public offerings, net of underwriting fees, transaction costs and stamp duty		11		—		103		1		—	—		104
Proceeds from sale of treasury shares in public offerings, net of underwriting fees and transaction costs		11		114		—		(114)		—	—		—
Issuance of shares, net of transaction costs:
Restricted share awards		18		23		3,489		—		(3,512)	—		—
Exercise of options		18		0		7		—		—	—		7
Balance as of December 31, 2024				2,226		478,506		(218)		(368,239)	(5)		112,270


							Currency
			Share	Share	Treasury	Accumulated	translation
		Note	capital	premium	shares	losses	differences	Total
Balance as of January 1, 2025			2,226	478,506	(218)	(368,239)	(5)	112,270
Loss for the period			—	—	—	(70,447)	—	(70,447)
Other comprehensive income/(loss)		17	—	—	—	(1,353)	12	(1,341)
Total comprehensive loss			—	—	—	(71,800)	12	(71,788)

Share-based payments		18	—	—	—	4,396	—	4,396
Issuance of shares, net of transaction costs:
Restricted share awards		18	26	3,352	—	(3,378)	—	—
Exercise of options		18	1	5	—	—	—	6
Balance as of December 31, 2025			2,253	481,863	(218)	(439,021)	7	44,884

The accompanying notes are an integral part of these consolidated financial statements.

AC Immune SA

Consolidated Statements of Cash Flows

(In CHF thousands)


		For the Year Ended
		December 31,
		Note		2025		2024		2023
Operating activities
Loss for the period				(70,447)		(50,916)		(54,233)
Adjustments to reconcile net loss for the period to net cash flows:
Depreciation of property, plant and equipment		4		1,393		1,485		1,672
Depreciation of right-of-use assets		5		1,110		677		543
Finance (income)/expense, net		14		803		57		922
Share-based compensation expense		18		4,396		5,470		4,365
Change in net employee defined benefit liability		17		(1,551)		(10)		888
Interest expense		5/14		189		131		176
(Gain)/loss on lease modifications		5		(73)		—		—
(Gain)/loss on sale of fixed assets				(15)		—		—
Changes in working capital:
(Increase)/decrease in prepaid expenses		8		330		2,135		(1,748)
(Increase)/decrease in accrued income		8		739		(853)		162
(Increase)/decrease in accounts receivable		9		—		14,800		(14,800)
(Increase)/decrease in other current receivables		10		180		(396)		(232)
(Decrease)/increase in accrued expenses		12		(3,861)		1,373		1,137
(Decrease)/increase in deferred contract revenue, short-term		13		(1,350)		85,056		—
(Decrease)/increase in deferred income				—		(138)		(449)
(Decrease)/increase in trade and other payables		12		(592)		977		770
(Decrease)/increase in deferred contract revenue, long-term		13		(2,221)		4,560		—
Cash provided by/(used in) operating activities				(70,970)		64,408		(60,827)
Interest received		14		1,897		1,563		595
Interest paid		5/14		(174)		(113)		(163)
Finance expenses paid		14		(15)		(16)		(13)
Net cash flows provided by/(used in) operating activities				(69,262)		65,842		(60,408)

Investing activities
Short-term financial assets, net		7		64,597		(104,660)		66,446
Purchases of property, plant and equipment		4		(900)		(576)		(801)
Proceeds from sale of property, plant and equipment		4		15		—		—
Rental deposits		5		(170)		(54)		—
Net cash flows provided by/(used in) investing activities				63,542		(105,290)		65,645

Financing activities
Proceeds from public offerings of common shares, net of underwriting fees and transaction costs		11		—		—		41,056
Proceeds from sale of treasury shares in public offerings, net of underwriting fees and transaction costs		11		—		104		2,677
Proceeds from issuance of common shares – equity plan, net of transaction costs		11		6		7		65
Transaction costs and stamp duty associated with the public offerings of common shares previously recorded in Accrued expenses		11		—		(521)		—
Transaction costs associated with the sale of treasury shares in public offering previously recorded in Accrued expenses		11		—		(27)		—
Principal payments of lease obligations		5		(1,026)		(683)		(548)
Net cash flows (used in)/provided by financing activities				(1,020)		(1,120)		43,250

Net increase/(decrease) in cash and cash equivalents				(6,740)		(40,568)		48,487

Cash and cash equivalents at January 1				36,275		78,494		31,586
Exchange gain/(loss) on cash and cash equivalents				(2,740)		(1,651)		(1,579)
Cash and cash equivalents at December 31				26,795		36,275		78,494

Net increase/(decrease) in cash and cash equivalents				(6,740)		(40,568)		48,487

Supplemental non-cash activity
Capital expenditures in Trade and other payables or Accrued expenses		4		15		184		—
Transaction costs and stamp duty associated with the public offerings of common shares recorded in Accrued expenses		11		—		—		521
Transaction costs associated with the sale of treasury shares in public offering recorded in Accrued expenses		11		—		—		27

The accompanying notes are an integral part of these consolidated financial statements.

AC Immune SA

Notes to the Consolidated Financial Statements

(In CHF thousands except for share and per share data)

1.General information

AC Immune SA was founded in 2003. The Company controls a fully-owned subsidiary, AC Immune USA, Inc. (“AC Immune USA” or “Subsidiary” and, together with AC Immune SA, “AC Immune,” “ACIU,” “Company,” “we,” “our,” “ours,” “us”), which was registered and organized under the laws of Delaware, USA in June 2021. The Company and its Subsidiary form the Group.

AC Immune SA is a clinical-stage biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel proprietary medicines and diagnostics for prevention and treatment of neurodegenerative diseases (NDD) associated with protein misfolding. Misfolded proteins are generally recognized as the leading cause of NDD, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), with common mechanisms and drug targets, such as amyloid beta (Abeta), Tau, alpha-synuclein (a-syn) and TDP-43. Our goal is to continue leveraging our proprietary discovery platforms, SupraAntigen and Morphomer, to shift the treatment paradigm for neurodegenerative disease towards Precision Medicine. Our corporate strategy is focused on two core value drivers: (i) Active Immunotherapies being developed for the treatment and prevention of Alzheimer’s disease (AD) and Parkinson’s disease (PD); and (ii) Intracellular targeting with brain penetrant small molecule programs targeting intracellular pathologies.

The Company was initially incorporated as a limited liability company on February 13, 2003 in Basel, and effective August 25, 2003 was transformed into a stock company. The Company’s corporate headquarters are located at EPFL Innovation Park Building B, 1015 Lausanne, Switzerland.

2.Basis of preparation

Going concern

The Company believes that it will be able to meet all of its obligations as they fall due for at least 12 months from the filing date of this Form 20-F, after considering the Company’s cash position of CHF 26.8 million and short-term financial assets of CHF 64.6 million as of December 31, 2025. Hence, these consolidated financial statements have been prepared on a going-concern basis.

To date, the Company has financed its cash requirements primarily from its public offerings, share issuances, contract revenues from option, license and collaboration agreements (OLCAs) and grants. The Company is a clinical stage company and is exposed to all the risks inherent to establishing a business. Inherent to the Company’s business are various risks and uncertainties, including the substantial uncertainty as to whether current projects will succeed and our ability to raise additional capital as needed. These risks may require us to take certain measures such as delaying, reducing or eliminating certain programs. The Company’s success may depend in part upon its ability to (i) establish and maintain a strong patent position and protection, (ii) enter into collaborations with partners in the pharmaceutical and biopharmaceutical industries, (iii) successfully move its product candidates through clinical development, (iv) attract and retain key personnel and (v) acquire capital to support its operations.

Statement of compliance

The consolidated financial statements have been prepared in accordance with IFRS Accounting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). These consolidated financial statements were approved for issue by the Board of Directors on March 11, 2026.

Basis of measurement

The consolidated financial statements have been prepared under the historical cost convention except for items that are required to be accounted for at fair value.

3.Summary of material accounting policies

The principal accounting policies adopted in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Functional and reporting currency

These consolidated financial statements and accompanying notes are presented in Swiss Francs (CHF), which is AC Immune SA’s functional currency and the Group’s reporting currency. The Company’s subsidiary has a functional currency of the U.S. Dollar (USD). The respective functional currency represents the primary economic environment in which the entities operate.

The following exchange rates have been used for the translation of the financial statements of AC Immune USA:


		For the Year Ended
		December 31,
		2025		2024		2023
CHF/USD
Closing rate, USD 1		0.800		0.912		0.851
Weighted average exchange rate, USD 1		0.840		0.889		0.908

The results and financial position of AC Immune USA are translated into the presentation currency as follows:

assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet;

ii.

income and expenses for each statement of income/(loss) are translated at average exchange rates; and

iii.

all resulting exchange differences are recognized in other comprehensive income/(loss), within cumulative translation differences.

Basis of consolidation

The annual closing date of the individual financial statements is December 31. The Company fully-owns its Subsidiary and fully consolidates its financial statements into these consolidated financial statements. All intercompany transactions have been eliminated.

Foreign currency transactions

Foreign currency transactions are translated into the respective functional currency using prevailing exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the consolidated statements of income/(loss). Any gains or losses from these translations are included in the consolidated statements of income/(loss) in the period in which they arise.

Current vs. non-current classification

The Company presents assets and liabilities in the consolidated balance sheets based on a current/non-current classification. The Company classifies as current all amounts (assets) that are to be realized within 12 months after the

reporting period and classifies as non-current all other amounts (assets). For liabilities, in accordance with IAS 1, any amounts expected to be settled within 12 months after the reporting period are classified as current if the Company does not have the right to defer settlement for at least 12 months after the reporting period - all other amounts (liabilities) are classified as non-current.

Revenue recognition

The Company applies IFRS 15 Revenue from Contracts with Customers. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, certain collaboration arrangements and financial instruments. Under IFRS 15, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of IFRS 15, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of IFRS 15, the Company assesses the goods or services promised within each contract, and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

The Company enters into OLCAs which are within the scope of IFRS 15, under which it licenses certain rights to its product candidates and intellectual property to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and/or commercial milestone payments; payments for research and clinical services the Company provides through either its full-time employees or third-party vendors, and royalties on net sales of licensed products commercialized from the Company’s intellectual property. Each of these payments results in license, collaboration and other revenues, which are classified as contract revenue on the consolidated statements of income/(loss).

Licenses of intellectual property

If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are sold in conjunction with a related service, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the performance obligation is settled over time, the Company determines the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Milestone payments

At the inception of each arrangement that includes development, regulatory and/or commercial milestone payments, the Company evaluates whether the milestones are considered highly probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is highly probable that a significant cumulative revenue reversal would not occur in future periods, the associated milestone value is included in the transaction price. These amounts for the performance obligations under the contract are recognized as they are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments recorded would affect contract revenues and earnings in the period of adjustment.

Research and development services

The Company has certain arrangements with our collaboration partners that include contracting our employees for research and development programs. The Company assesses if these services are considered distinct in the context of each contract and, if so, they are accounted for as separate performance obligations. These revenues are recorded in contract revenue as the services are performed.

Sublicense revenues

The Company has certain arrangements with our collaboration partners that include provisions for sublicensing. The Company recognizes any sublicense revenues at the point in time it is highly probable to obtain and not subject to reversal in the future.

Contract balances

The Company receives payments and determines credit terms from its customers for its various performance obligations based on billing schedules established in each contract. The timing of revenue recognition, billings and cash collections results in billed other current receivables, accrued income (contract assets), and deferred income (contract liabilities) on the consolidated balance sheets. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be 1 year or less.

For a complete discussion of accounting for contract revenue, see “Note 13. Contract revenues.”

Research and development expenses

Given the stage of development of the Company’s products, all research and development expenditure is expensed as incurred as it does not meet the capitalization criteria outlined in IAS 38 Intangible Assets. The Company has not capitalized any R&D expenses to date. Research and development expenditures include:

●

the cost of acquiring, developing and manufacturing active pharmaceutical ingredients for product candidates that have not received regulatory approval, clinical trial materials and other research and development materials;

●

fees and expenses incurred under agreements with contract research organizations, investigative sites and other entities in connection with the conduct of clinical trials and preclinical studies and related services, such as administrative, data-management and laboratory services;

●

fees and costs related to regulatory filings and activities;

●

costs associated with preclinical and clinical activities;

●

employee-related expenses, including salaries and bonuses, benefits, travel and share-based compensation expenses; and

●

all other allocated expenses such as facilities and information technology (IT) costs.

with our CRO or CMO vendors to gauge the reasonableness of our estimates and accrued expenses as of the balance sheet date in the consolidated financial statements based on facts and circumstances known at the time.

Registration costs for patents are part of the expenditure for research and development projects. Therefore, registration costs for patents are expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization.

General and administrative expenses

General and administrative expenses are expensed as incurred and include personnel costs, expenses for outside professional services and all other allocated expenses. Personnel costs consist of salaries, cash bonuses, benefits and share-based compensation. Outside professional services consist of legal, accounting and audit services, IT and other consulting fees. Allocated expenses consist of certain IT, facilities and depreciation expenses.

Restructuring expenses

During September 2025, the Company incurred restructuring costs associated with planned initiatives to reduce its costs. The most significant restructuring costs are termination benefits provided to employees. In connection with developing a detailed formal plan for the restructuring, the Company established a provision for restructuring costs and, through execution of the plan and announcement of its main features to those affected by it, a valid expectation has been raised in those affected that the plan would be implemented.

Grant income

The Company has received grants, from time to time, from the Michael J. Fox Foundation (MJFF), the Target ALS Foundation (Target ALS) and other institutions to support certain research projects. Grants are recorded at their fair value in the consolidated statements of income/(loss) within other operating income/(expenses), net when there is reasonable assurance that the Company will satisfy the underlying grant conditions and the grants will be received. In certain circumstances, grant income may be recognized before formal grantor acknowledgement of milestone achievements. To the extent required, grant income is deferred and recognized on a systematic basis over the periods in which the Company expects to recognize the related expenses for which the grants are intended to compensate.

Leases

The Company applies IFRS 16 Leases, which provides the model for lessee accounting in which all leases, other than short-term and low-value leases, are accounted for by the recognition on the consolidated balance sheet of a right-of-use asset and a lease liability, and the subsequent amortization of the right-of-use asset over the earlier of the end of the useful life or the lease term. In accordance with IFRS 16, the Company (i) does not recognize right-of-use assets and lease liabilities for leases of low value (i.e. approximate fair value of USD 5,000). For a complete discussion of accounting, see “Note 5. Right-of-use assets, long-term financial assets and lease liabilities.”

Right-of-use assets and lease liabilities

At inception of a leasing contract, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the lease commencement date. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate. The lease liabilities are classified as current or non-current based on the due dates of the underlying principal payments.

Lease payments generally are fixed for the contract term. The lease liability is measured at amortized cost using the effective interest method. The lease liability is re-measured if there is a change in the estimated lease term, a change in future lease payments arising from a change in an index or rate, a change in the Company’s estimate of the amount

expected to be payable under a residual value guarantee or a change in assessment of whether it will exercise a purchase, extension or termination option.

At inception, the right-of-use asset comprises the initial lease liability and any initial direct costs. The right-of-use asset is depreciated over the shorter of the lease term or the useful life of the underlying asset. The right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability performed on as certain potential triggering events may arise (e.g. lease modifications). When the lease liability is re-measured, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.

The estimated lease term by right-of-use asset categories are as follows:


Buildings	5	years
Office equipment	5	years
IT equipment	5	years

Both the right-of-use-assets and lease liabilities are recognized in the consolidated balance sheets.

Property, plant and equipment

Equipment is shown at historical acquisition cost, less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures that are directly attributable to the acquisition of the property, plant and equipment. Depreciation is calculated using a straight-line method to write off the cost of each asset to its residual value over its estimated useful life as follows:


IT equipment	3	years
Laboratory equipment	5	years
Leasehold improvements/furniture	5	years

The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at each balance sheet date. Where an asset’s carrying amount is greater than its estimated recoverable amount, it is written down to its recoverable amount.

Gains and losses on disposals are determined by comparing the disposal proceeds with the carrying amount and are included in the consolidated statements of income/(loss).

Intangible assets

AC Immune’s acquired in process research and development (IPR&D) asset is stated at cost less any impairments. The Company does not deem this asset ready for use until the asset obtains market approval. Therefore, during the development period after the date of acquisition until market approval, the IPR&D asset is not amortized. Upon market approval, the Company will determine the useful life of the asset, reclassify it from IPR&D and commence amortization. If the associated R&D effort is abandoned, the related IPR&D will likely be written off and we will record the relevant impairment charge. Finally, the Company will not capitalize future development costs in respect to this IPR&D asset until they meet the criteria for capitalization of research and development costs in accordance with IAS 38 Intangible Assets.

Our IPR&D asset is subject to impairment testing at least annually or when there are indications that the carrying value may not be recoverable until the completion of the development process. The determination of the recoverable amounts include key estimates which are highly sensitive to, and dependent upon, key assumptions.

The Company uses a discounted cash flow method to determine the fair value less costs to sell (recoverable amount) of our IPR&D intangible asset. The Company starts with a forecast of all the expected net cash flows, which

incorporates the consideration of a terminal value and then the Company applies a discount rate to arrive at a risk-adjusted net present value amount.

Any impairment losses are recognized immediately in the consolidated statements of income/(loss).

Fair value of financial assets and liabilities

The Company’s financial assets and liabilities are composed of receivables, short-term financial assets, cash and cash equivalents, trade payables and lease liabilities. The fair value of these financial instruments approximates their respective carrying values due to the short-term maturity of these instruments, and are held at their amortized cost in accordance with IFRS 9, unless otherwise explicitly noted.

Receivables

Receivables are recognized at their billing value. An allowance for doubtful accounts is recorded for potential estimated losses when there is evidence of the debtor’s inability to make required payments and the Company assesses on a forward-looking basis the expected credit losses associated with these receivables held at amortized cost.

Short-term financial assets

Short-term financial assets are held with external financial institutions and comprise fixed-term deposits with maturities ranging from more than 3 through 12 months in duration.

The Company assesses whether there is objective evidence that financial assets are impaired annually or whenever potential impairment triggers may occur.

Cash and cash equivalents

Trade payables

Trade payables are amounts due to third parties in the ordinary course of business.

Share capital and public offerings

Common shares are classified as equity. Share issuance costs are capitalized as incurred and will be shown in equity as a deduction, net of tax, from the proceeds received from existing or future offerings. Should a planned equity offering not be assessed as probable, the issuance costs would be expensed immediately in the consolidated statements of income/(loss). See “Note 11. Share capital.”

Treasury shares

Treasury shares are recognized at acquisition cost and deducted from shareholders’ equity at the time of acquisition, until they are subsequently resold, distributed or cancelled. Where such shares are subsequently sold, any consideration received is included in shareholders’ equity. See “Note 11. Share capital.”

Employee benefits

Post-employment benefits

The Company operates the mandatory pension schemes for its employees in Switzerland. The schemes are generally funded through payments to insurance companies. The Company has a pension plan designed to pay pensions based on accumulated contributions on individual savings accounts. However, this plan is classified as a defined benefit plan under IAS 19.

The net defined benefit liability is the present value of the defined benefit obligation at the balance sheet date minus the fair value of plan assets. Significant estimates are used in determining the assumptions incorporated in the calculation of the pension obligations, which is supported by input from independent actuaries. The defined benefit obligation is calculated annually with the assistance of an independent actuary using the projected unit credit method, which reflects services rendered by employees to the date of valuation, incorporates assumptions concerning employees’ projected salaries and pension increases as well as discount rates of highly liquid corporate bonds that have terms to maturity approximating the terms of the related liability.

To the extent that the fair value of the plan assets is greater than the present value of the defined benefit obligation as calculated by our independent actuary, the Company accounts for the effect of the asset ceiling test under IAS 19.

Re-measurements of the net defined benefit liability, which comprise actuarial gains and losses and the return on plan assets (excluding interest) are recognized immediately in the consolidated statements of other comprehensive income/(loss). Past service costs, including curtailment gains or losses, are recognized immediately allocated to the appropriate operating results category, including research and development, general and administrative expenses, or restructuring expenses as applicable. Settlement gains or losses are recognized in either research and development and/or general and administrative expenses within the operating results. The Company determines the net interest expense/(income) on the net defined benefit liability for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement dates to the then-net defined benefit liability, considering any changes in the net defined benefit liability during the period as a result of contributions and benefit payments. Net interest expense/(income) and other expenses related to defined benefit plans are recognized in the consolidated statements of income/(loss).

Share-based compensation

The Company operates an equity-settled, share-based compensation plan. The fair value of the employee services received in exchange for the grant of equity-based awards is recognized as an expense. The total amount to be expensed over the vesting period is determined by reference to the fair value of the instruments granted, excluding the impact of any non-market vesting conditions. Non-market vesting conditions are included in assumptions about the number of instruments that are expected to become exercisable. At each balance sheet date, the Company revises its estimates of the number of instruments that are expected to become exercisable. It recognizes the impact of the revision of original estimates, if any, prospectively in the consolidated statements of income/(loss), and a corresponding adjustment to equity over the remaining vesting period.

Stock options granted under the Company’s stock option plans C1 and the 2016 Stock Option and Incentive Plan are valued using the Black-Scholes option-pricing model (see “Note 18. Share-based compensation”). This valuation model as well as parameters used such as expected volatility and expected term of the stock options are partially based on management’s estimates.

The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised.

We estimate the fair value of restricted share units using the market value of the common shares on the date of the award. We classify our share-based payments as equity-classified awards as they are settled in common shares. We measure equity-classified awards at their grant date fair value and do not subsequently re-measure them. Compensation

costs related to equity-classified awards are equal to the fair value of the award at grant date amortized over the vesting period of the award using the graded method. We reclassify that portion of vested awards to share capital and share premium as the awards vest.

Provisions

Provisions are recognized when the Company has a present legal or constructive obligation as a result of past events where it is more likely than not that an outflow of resources will be required to settle the obligation, and a reliable estimate of the amount can be made.

Taxation

Current income tax assets and liabilities for the period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the tax amounts are those that are enacted or substantively enacted, at the reporting date in accordance with the fiscal regulations of the respective country where the Company operates and generates taxable income. Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. If required, deferred taxation is provided in full using the liability method, on all temporary differences at the reporting dates. It is calculated at the tax rates that are expected to apply to the period when it is anticipated the liabilities will be settled, and it is based on tax rates (and laws) that have been enacted or substantively enacted at the reporting date.

Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. Although the Company has substantial tax loss carry-forwards, historically, due to the fact that the Company had limited certainty on the achievement of key milestones, it has not recognized any deferred tax assets because it’s more likely than not that it will not be recovered.

As disclosed in “Note 16. Income taxes,” the Company has tax losses that can generally be carried forward for a period of 7 years from the period the loss was incurred. These tax losses represent potential value to the Company to the extent that the Company is able to create taxable profits before the expiry period of these tax losses. The Company has not recorded any deferred tax assets in relation to these tax losses.

Earnings per share

The Company presents basic earnings per share for each period in the consolidated financial statements. The earnings per share are calculated by dividing the earnings of the period by the weighted-average number of shares outstanding during the period. Diluted earnings per share reflect the potential dilution that could occur if dilutive securities such as share options or non-vested restricted share units were vested or exercised into common shares or resulted in the issuance of common shares that would participate in net income. Anti-dilutive shares are excluded from the dilutive earnings per share calculation.

Critical judgments and accounting estimates

The preparation of financial statements in conformity with IFRS Accounting Standards requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses.

The areas where AC Immune has had to make judgments, estimates and assumptions relate to (i) revenue recognition on OLCAs (Note 13), (ii) clinical development accruals (Note 12), (iii) net employee defined benefit liability (Note 17), (iv) share-based compensation (Note 18), (v) right-of-use assets and lease liabilities (Note 5) and (vi) our IPR&D asset (Note 6). Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Segment reporting

The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins.

The Company is managed and operated as one business. The chief operating decision maker comprehensively manages the entire business as one segment. Accordingly, the Company views its business and manages its operations as one operating segment. Non-current assets are located in, and revenue is allocated and recorded within, the Company’s country of domicile, Switzerland.

Accounting policies, standards, interpretations and amendments adopted by the Company

There are no new IFRS standards, amendments or interpretations that are mandatory as of January 1, 2025 that are relevant to the Company. Additionally, the Company has not adopted any standard, interpretation or amendment that has been issued but is not yet effective. Such standards are not currently expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.

New standards that are not yet effective

In April 2024, the IASB issued IFRS 18 Presentation and Disclosure in Financial Statements (IFRS 18). The new standard on presentation and disclosure in the financial statements will change the structure of the statement of profit or loss, require disclosures for certain profit or loss performance measure that are reported outside of the financial statements, and will enhance principles on aggregation and disaggregation within the notes to the financial statements. It also establishes a new starting point and revised requirements for interest and dividends in the statement of cash flows. This new standard will be effective for annual and interim reporting periods beginning on January 1, 2027 and will require retrospective application. The Company is currently evaluating the new standard to determine how it will impact the presentation and disclosure in its financial statements.

In May and December 2024, the IASB issued narrow scope amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures. These amendments clarify the requirements for determining contractual cash flows of financial assets, financial liabilities and lease liabilities, as well as guidance on contracts referencing nature-dependent electricity. These amendments are effective January 1, 2026. The Company is currently evaluating the new standard to determine how it will impact the presentation and disclosure in its financial statements, at this time the amendments are not expected to have a material impact on the presentation and disclosure in its financial statements.

4.Property, plant and equipment

The following tables show the movements in the net book values of property, plant and equipment for the years ended December 31, 2025 and 2024, respectively:


		As of December 31, 2025
				IT		Laboratory		Leasehold
In CHF thousands		Furniture		equipment		equipment		improvements		Total
Acquisition cost:
Balance at December 31, 2024		333		2,387		10,536		1,863		15,119
Additions		1		158		545		27		731
Disposals		—		—		(146)		—		(146)
Balance at December 31, 2025		334		2,545		10,935		1,890		15,704

Accumulated depreciation:
Balance at December 31, 2024		(258)		(2,056)		(9,053)		(1,101)		(12,468)
Depreciation expenses		(32)		(221)		(847)		(293)		(1,393)
Disposals		—		—		146		—		146
Balance at December 31, 2025		(290)		(2,277)		(9,754)		(1,395)		(13,715)

Carrying amount:
December 31, 2024		75		331		1,483		762		2,651
December 31, 2025		44		269		1,182		495		1,989


		As of December 31, 2024
				IT		Laboratory		Leasehold
In CHF thousands		Furniture		equipment		equipment		improvements		Total
Acquisition cost:
Balance at December 31, 2023		309		2,168		10,233		1,662		14,372
Additions		24		219		316		201		760
Disposals		—		—		(13)		—		(13)
Balance at December 31, 2024		333		2,387		10,536		1,863		15,119

Accumulated depreciation:
Balance at December 31, 2023		(212)		(1,851)		(8,101)		(832)		(10,996)
Depreciation expenses		(46)		(205)		(965)		(269)		(1,485)
Disposals		—		—		13		—		13
Balance at December 31, 2024		(258)		(2,056)		(9,053)		(1,101)		(12,468)

Carrying amount:
December 31, 2023		97		317		2,133		830		3,377
December 31, 2024		75		331		1,483		762		2,651

For the years ended December 31, 2025, 2024 and 2023, the Company incurred CHF 1.4 million, CHF 1.5 million and CHF 1.7 million in depreciation expenses, respectively.

5.Right-of-use assets, long-term financial assets and lease liabilities

The Company recognized additions and reassessment of right-of-use of leased assets for buildings or for office equipment totaling CHF 0.2 million and CHF 2.6 million for the years ended December 31, 2025 and 2024, respectively. In 2025, the change pertained to a reduction of lease space, offset by the reassessment of the lease term of a separate

lease space. In 2024, the increase was predominantly associated with a new lease and the reassessment of our existing leased office space.

Regarding lease liabilities, the amortization depends on the rate implicit in the contract or the incremental borrowing rate for the respective lease component. The weighted averages of the incremental borrowing rates as of December 31, 2025 are 5.5% (3.5% for 2024) for buildings, 3.3% (3.3% for 2024) for office equipment and 7.2% (7.2% for 2024) for IT equipment.

The following tables show the movements in the net book values of right-of-use of leased assets for the years ended December 31, 2025 and 2024, respectively:


				Office		IT
In CHF thousands		Buildings		equipment		equipment		Total
Balance as of December 31, 2024		5,320		91		26		5,437
Lease modification and reassessment		213		—		—		213
Depreciation		(1,064)		(40)		(6)		(1,110)
Balance as of December 31, 2025		4,469		51		20		4,540


				Office		IT
In CHF thousands		Buildings		equipment		equipment		Total
Balance as of December 31, 2023		3,446		50		12		3,508
Additions and reassessment		2,516		64		26		2,606
Depreciation		(642)		(23)		(12)		(677)
Balance as of December 31, 2024		5,320		91		26		5,437

For the years ended December 31, 2025, and 2024, the impact on the Company’s consolidated statements of income/(loss) and consolidated statements of cash flows is detailed in the table below.


	For the Year Ended
	December 31,
In CHF thousands	2025		2024
Statements of income/(loss)
Depreciation of right-of-use assets	1,110		677
Interest expense on lease liabilities	174		113
Expense for short-term leases and leases of low value	690		752
Total	1,975		1,542

Statements of cash flows
Total cash outflow for leases	1,891		1,549

The following table presents the contractual undiscounted cash flows for lease liabilities as of December 31, 2025 and 2024:


		As of
		December 31,
In CHF thousands		2025		2024
Less than one year		1,079		1,200
1-3 years		2,077		2,372
3-5 years		2,038		2,352
Total		5,194		5,924

The Company also has two deposits in escrow accounts totaling CHF 0.6 million and CHF 0.4 million for the lease of the Company’s premises as of December 31, 2025 and 2024, respectively.

6.Intangible assets

AC Immune’s acquired IPR&D asset is a clinically-validated active immunotherapy candidate for the treatment of Parkinson’s disease. The asset is not yet ready for use until the asset obtains market approval. The carrying amount and net book value are detailed below:

 

As of December 31, 2025

As of December 31, 2024

Gross

carrying

Accumulated

Net book

carrying

Accumulated

Net book

In CHF thousands

amount

amortization

value

amount

amortization

value

Acquired IPR&D asset

50,416

—

50,416

—

50,416

Total intangible assets

50,416

—

50,416

—

50,416

In accordance with IAS 36 Impairment of Assets, the IPR&D asset is reviewed at least annually for impairment by assessing the fair value less costs to sell (recoverable amount) and comparing this to the carrying value of the asset. The valuation is considered to be Level 3 in the fair value hierarchy in accordance with IFRS 13 Fair Value Measurement due to unobservable inputs used in the valuation. The Company has determined the IPR&D asset was not impaired as of December 31, 2025 and 2024, respectively.

The key assumptions used in the valuation model in accordance with an income approach to determine the recoverable amount include observable and unobservable key inputs as follows:

●

Anticipated research and development costs;

●

Anticipated costs of goods and sales and marketing expenditures;

●

Probability of achieving clinical and regulatory development milestones in accordance with certain industry benchmarks;

●

Target indication prevalence and incidence rates;

●

Anticipated market share;

●

General commercialization expectations such as anticipated pricing and uptake;

●

Expected patent life and market exclusivity periods; and

●

Other metrics such as the tax rate.

The Company’s valuation model calculates the risk-adjusted, net cash flows through the projected period of market exclusivity across target sales regions. The Company uses a discount rate of 16% (17% for 2024), based on the assumed cost of capital for the Company over the forecast period.

7.Cash and cash equivalents and short-term financial assets

The Company’s cash and cash equivalents are maintained in the following respective currencies as of December 31, 2025 and 2024:


		As of
		December 31,
In CHF thousands		2025		2024
Cash and cash equivalents		26,795		36,275
Total		26,795		36,275
By currency
CHF		21,815		20,798
EUR		3,632		7,308
USD		1,221		8,169
Other		127		—
Total cash and cash equivalents		26,795		36,275

As of December 31, 2025 and 2024, the Company’s funds were predominantly held in CHF, EUR and USD currencies. Funds held in EUR and USD were translated into CHF at a rate of 0.940 and 0.800 and 0.949 and 0.912, respectively, for each currency and year.

The following table summarizes the Company’s short-term financial assets as of December 31, 2025 and 2024:


		As of
		December 31,
In CHF thousands		2025		2024
Short-term financial assets due in one year or less		64,617		129,214
Total		64,617		129,214
By currency
CHF		37,068		95,006
EUR		17,384		18,705
USD		10,165		15,503
Total short-term financial assets		64,617		129,214

8.Prepaid expenses and accrued income


		As of
		December 31,
In CHF thousands		2025		2024
Prepaid expenses		3,972		4,302
Accrued income		360		1,099
Total prepaid expenses and accrued income		4,332		5,401

The Company’s prepaid expenses relate mainly to research contracts with down-payments at contract signature with the related activities to start or continue into the next year, prepaid expenses recorded as part of our cost sharing arrangement with Janssen, as well as prepaid payroll-related expenses. The decrease in prepaid expenses is mainly due to the reduction in cost-sharing prepaid expenses, which decreased as our clinical development costs for ACI-35.030 decreased following the completion of Phase 1b/2a and the advancement into Phase 2b, where the costs are borne by Janssen.

As of December 31, 2025, the Company recorded CHF 0.4 million in accrued income from interest on cash term deposits, compared to CHF 1.1 million as of December 31, 2024.

9.Restructuring

On September 4, 2025, the Company announced that following a strategic review, the Company would sharpen its focused investment on its most important assets and implementing cost reduction measures accordingly. As a result of the initiatives announced in September 2025, the Company recorded CHF 0.5 million of net restructuring expenses in 2025, comprising CHF 2.1 million of termination benefits to be paid to the employees impacted by the restructuring, a CHF 1.8 million gain on curtailment related to the defined benefit liability, and less than CHF 0.1 million of expenses related to the acceleration of share-based compensation expenses.

As of December 31, 2025, the Company had a provision of CHF 0.3 million for termination benefits recorded under accrued expenses, compared to a provision of nil at the beginning of the year. The costs remaining in the provision are expected to be paid during the first quarter of 2026.

The curtailment event required a remeasurement of the defined benefit liability using updated actuarial assumptions and current fair value of plan assets, in accordance with IAS 19. The impact of the curtailment is to be recognized in the same period as the restructuring. As a result of the curtailment, the Company recognized a CHF 1.8 million gain in 2025, compared to nil in the corresponding years 2024 and 2023. The curtailment gain is non-cash and arises due to the acceleration or elimination of future benefit accruals under the defined benefit plan.

10.Other current receivables


		As of
		December 31,
In CHF thousands		2025		2024
Other current receivable		80		144
Swiss VAT		241		271
Withholding tax		657		689
Total other current receivables		978		1,104

The maturity of these assets is less than 3 months. The Company considers the counterparty risk as low and the carrying amount of these receivables is considered to approximate their fair value.

11.Share capital

As of December 31, 2025 and 2024, the issued share capital amounted to CHF 2,252,840 and CHF 2,226,203, respectively, and is composed of outstanding common shares of 101,742,231 and 100,410,377, respectively, and treasury shares of 10,899,773 and 10,899,773, respectively.

The table below summarizes the Company’s capital structure:


						In CHF thousands
		Common		Treasury		Share		Share		Treasury
		shares		shares		capital		premium		shares
December 31, 2023		104,441,787		(5,243,958)		2,089		474,907		(105)
Proceeds from public offerings, net of underwriting fees and transaction costs		—		30,232		—		103		1
Proceeds from sale of treasury shares in public offerings, net of underwriting fees and transaction costs		5,700,000		(5,700,000)		114		—		(114)
Issuance of shares – incentive plans, net of transaction costs		1,168,363		13,953		23		3,496		—
December 31, 2024		111,310,150		(10,899,773)		2,226		478,506		(218)
Issuance of shares – incentive plans, net of transaction costs		1,331,854		—		27		3,357		—
December 31, 2025		112,642,004		(10,899,773)		2,253		481,863		(218)

The common shares and treasury shares have nominal values of CHF 0.02 per share. All shares have been fully paid. These treasury shares held by the Company are not considered outstanding shares as of December 31, 2025 or 2024.

Conditional share capital for financing and other purposes

The Company’s share capital may be increased by a maximum aggregate amount of CHF 100,000 through the issuance of a maximum of 5,000,000 registered shares, payable in full, each with a nominal value of CHF 0.02 per share, through the exercise of conversion and/or option or warrant rights granted in connection with bonds or similar instruments, issued or to be issued by the Company or by subsidiaries of the Company, including convertible debt instruments.

Conditional share capital for employee benefit plans

The Company’s share capital may be increased by a maximum aggregate amount of CHF 90,057.34 through the issuance of not more than 4,502,867 common shares, payable in full, each with a nominal value of CHF 0.02 per share, by the exercise of options rights that have been granted to employees, consultants, members of the board of directors, or other person providing services to the Company or a subsidiary. As of December 31, 2025, 168,677 of our common shares, which were issued upon the exercise of options and restricted share units, have not yet been registered with the commercial register of the Canton of Vaud.

Follow-On Offering

On December 19, 2023, the Company announced that it had closed an underwritten offering of 14,300,000 common shares, resulting in gross proceeds of approximately USD 50.1 (CHF 43.8) million. Net underwriting fees and transaction costs totaled CHF 3.3 million for net proceeds of CHF 40.5 million. Transaction costs associated with these offerings and related to the issuance of new shares were charged directly against the share premium account thereby reducing the total equity reported.

Shelf registration statement

On March 14, 2024, the Company filed a Shelf Registration Statement on Form F-3 (Reg. No. 333-277940) (the “Shelf Registration Statement”), which was subsequently amended on July 26, 2024, with the SEC. The Shelf Registration Statement was declared effective by the SEC on July 31, 2024.

The Shelf Registration Statement allows the Company to offer and sell, from time to time, up to USD 350,000,000 of common shares, debt securities, warrants, purchase contracts, units, subscription rights or any combination of the foregoing in one or more future public offerings. The terms of any future offering would be determined at the time of the offering and would be subject to market conditions and approval by the Company’s Board of Directors. Any offering of securities covered by the Shelf Registration Statement will be made only by means of a written prospectus and prospectus supplement authorized and filed by the Company.

At the market equity offering

In Q2 2021 and Q2 2024, we filed a new registration statement on Form F-3 and entered into a new Sales Agreement in Q2 2021 and Q3 2024 to replace and extend the ATM program.

In Q2 2024, the Company issued 5,700,000 common shares with a nominal value of CHF 0.02 to be held as treasury shares.

Through December 31, 2025, the Company has cumulatively sold 2,179,434 common shares previously held as treasury shares pursuant to the Sales Agreement, raising USD 16.4 (CHF 14.9) million, net of underwriting fees and transaction costs. We have paid commissions to Jefferies totaling USD 0.5 (CHF 0.5) million through December 31, 2025, for share issuances in accordance with our ATM programs. In 2025, the Company had no share activity related to the ATM program.

12.Trade and other payables and accrued expenses


	As of
	December 31,
In CHF thousands	2025	2024
Trade and other payables	2,068	2,658
Total trade and other payables	2,068	2,658

Accrued research and development costs	2,410	6,505
Accrued payroll expenses	4,238	4,176
Restructuring provision	290	—
Other accrued expenses	1,128	1,417
Total accrued expenses	8,067	12,098

The decrease in trade payables and accrued research and development costs is primarily due a decrease in research and development expenses in 2025 leading up to and at year end including reduced activities in early-stage programs and reduction in manufacturing activities on clinical stage programs which did not recur in the current year.

13.Contract revenues

For the years ended December 31, 2025, 2024 and 2023, AC Immune generated contract revenues of CHF 3.6 million, CHF 27.3 million and CHF 14.8 million, respectively.

The following tables provide contract revenue amounts from its OLCAs for the years ended December 31, 2025, 2024 and 2023, respectively.


	For the Year Ended
	December 31,
In CHF thousands	2025	2024	2023
Janssen	—	24,600	14,800
Takeda	3,573	2,709	—
Other	—	—	1
Total contract revenues	3,573	27,309	14,801

During the years ended December 31, 2025, 2024 and 2023, the Company recognized the following contract revenues as a result of changes in the contract asset and the contract liability balances in the respective periods:


	For the Year Ended
	December 31,
In CHF thousands	2025	2024	2023
Revenues recognized in the period from:
Amounts included in the contract liability at the beginning of the period	3,573	—	—
Performance obligations satisfied in previous periods	—	24,600	14,801

13.1 Licensing and collaboration agreements

Morphomer Tau small molecule – 2018 license agreement with Eli Lilly and Company

In December 2018, we entered into an exclusive, worldwide licensing agreement with Eli Lilly and Company (Lilly) to research and develop Morphomer Tau small molecules for the treatment of AD and other neurodegenerative diseases. More specifically, this is an exclusive license with the right to Lilly to grant sublicenses under the ACIU Patents, the ACIU know-how, and ACIU’s interests in the Joint Patents and the joint know-how to Exploit the Licensed Compounds and Licensed Products. The agreement became effective on January 23, 2019 (the “effective date”) when the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired. In Q3 2019, the Company and Lilly entered into the first amendment to divide the first discretionary milestone payment under the agreement of CHF 60 million into two installments, with the first CHF 30 million paid in Q3 2019 and the second CHF 30 million to be paid on or before March 31, 2020 unless Lilly terminated the agreement earlier. In Q1 2020, the Company and Lilly entered into a second amendment to replace the second CHF 30 million to be paid on or before March 31, 2020 with two milestone payments, one of CHF 10 million to be paid on or before March 31, 2020 and the other of CHF 60 million following the first patient dosed in a Phase 2 clinical study of a licensed product in the U.S. or EU.

Per the terms of the agreement, the Company received an initial upfront payment of CHF 80 million in Q1 2019 for the rights granted by the Company to Lilly. To date, the Company has completed a Phase 1 clinical study with ACI-3024.

Additionally, the Company and Lilly have continued candidate characterization across the research program, identifying new and highly differentiated candidates with desired cerebrospinal fluid exposure and selectivity for pathological aggregated Tau. These will be broadly developed in Tau-dependent neurodegenerative diseases by Lilly. Lilly is responsible for leading and funding further clinical development and will retain global commercialization rights for all indications.

Per the terms of the agreement, the Company may become eligible to receive additional milestone payments totaling up to approximately CHF 880 million for clinical and regulatory milestones and CHF 900 million upon achievement of certain commercial milestones. In addition to milestones, we will be eligible to receive royalties on sales at a percentage rate ranging from the low double-digits to the mid-teens. The agreement will terminate by the date of expiration of the

last royalty term for the last licensed product. However, under the terms of the agreement, Lilly may terminate the agreement at any time by providing 3 months’ prior notice to us.

AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Lilly is a customer. The Company identified the following significant performance obligations under the contract: (i) a right-of-use license and (ii) research and development activities outlined in the development plan. Per the agreement, the Company was responsible for the preclinical and Phase 1 activities for the first clinical candidate, ACI-3024, which the Company determined was distinct and capable of being completed by Lilly or a third party. Preclinical activities for which AC Immune was responsible prior to their completion in Q2 2019 included final manufacturing of materials for use in the regulatory submission of the protocol and in the Phase 1 study. For the completed Phase 1, AC Immune was responsible for leading the study design, obtaining relevant regulatory agency approvals, arranging necessary third-party contracts, completing patient selection, ensuring patient treatment, following up with patients, drafting the clinical study report development and other relevant clinical activities to ensure that the primary objective of the study was completed. The Company used CMOs for certain of its preclinical activities and CROs to complete certain Phase 1 activities and to issue the final clinical study report.

Finally, per the agreement, each party has three representatives on a joint steering committee (JSC). Depending upon the agenda, additional field experts can attend the JSC to provide the technical and scientific contribution required. The JSC meets on a regular basis depending on agreements between the representatives. The JSC is responsible for serving as the forum to (i) discuss, review and approve certain activities by reviewing and discussing the development progress with updates on back-up candidates, (ii) discuss, review and approve all amendments to the global development plan, (iii) periodically discuss and review commercialization of licensed products and (iv) review and approve reports related to development costs among other activities. The JSC is intended to ensure that communication between the parties remains consistent and that the development plan is progressing as intended.

The valuation of each performance obligation involves estimates and assumptions with revenue recognition timing to be determined by either delivery or the provision of services.

The Company used the residual approach to estimate the selling price for the right-of-use license and an expected cost plus margin approach for estimating the research and development activities. The right-of-use license was delivered on the effective date. The research and development activities were delivered over time as the services were performed. For these services, revenue was recognized over time using the input method, based on costs incurred to perform the services, as the level of costs incurred over time is thought to best reflect the transfer of services to Lilly. The Company determined the value of the research and development activities to be CHF 6.9 million and deferred this balance from the effective date. To date, the Company has cumulatively recognized CHF 6.9 million in contract revenue, resulting in no deferred income (contract liability) on the consolidated balance sheets. The remaining CHF 73.1 million from the upfront payment was allocated to the right-of-use license and recognized on the effective date.

At inception of the agreement, none of the clinical, regulatory or commercial milestones had been included in the transaction price, as all milestone amounts were fully constrained. To date, the Company has recognized CHF 40 million from milestone payments triggered in Q3 2019 and Q1 2020 related to the right-of-use license for intellectual property as there were no further constraints related to these milestones. In assessing that future clinical, regulatory or commercial milestones are fully constrained, the Company considered numerous factors to determine that these milestones are not highly probable to obtain, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Lilly and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

For the years ended December 31, 2025, 2024 and 2023, we have recognized no revenues from this arrangement.

Tau active immunotherapy in AD – 2014 agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company

In December 2014, we entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize therapeutic anti-Tau active immunotherapies for the treatment of AD and potentially other tauopathies. The value of this collaboration is potentially up to CHF 500 million and includes upfront and clinical, regulatory and commercial milestones. In addition to milestones, we will be eligible to receive royalties on sales at a percentage rate ranging from the low-double digits to the mid-teens for the ACI-35.030 active immunotherapy program. In April 2016, July 2017, January 2019, November 2019, December 2022, November 2023, September 2024 and December 2024, the companies entered into the first, second, third, fourth, fifth, sixth, seventh and eighth amendments, respectively. These amendments allow for the alignment of certain payment and activity provisions with the Development Plan and Research Plan activities. We and Janssen have completed the co-development of the second-generation lead active immunotherapies, ACI-35.030 and JACI-35.054, through Phase 1b/2a. In November 2022, it was announced that ACI-35.030 was selected to advance into further development based on interim data from the ongoing Phase 1b/2a trial. In December 2023, it was announced that Janssen has programmed the launch of Phase 2b clinical study to evaluate ACI-35.030/JNJ-2056 in patients with preclinical AD, those individuals not yet showing symptoms. AC Immune and Janssen will jointly share research and development costs until the completion of the first Phase 2b (AC Immune’s contribution to the first Phase 2b trial is capped). From Phase 2b and onwards, Janssen will assume responsibility for the clinical development, manufacturing and commercialization of ACI-35.030. In July 2024, JNJ-2056 was granted Fast Track designation from the FDA, for the treatment of AD.

Under the terms of the agreement, Janssen may terminate the agreement at any time after completion of the first Phase 1b clinical study in 2016 by providing 90 days’ notice to us. If not otherwise terminated, the agreement shall continue until the expiration of all royalty obligations as outlined in the contract.

The agreement also allows for the expansion to a second indication based on the same anti-Tau active immunotherapy program and based on intellectual property related to this program.

The Company received an upfront, non-refundable license fee of CHF 25.9 million, which we recognized as revenue in 2014. In May 2016, we received a payment of CHF 4.9 million for reaching a clinical milestone in the first Phase 1b study. In February 2024, we received a payment of CHF 14.8 million for the commencement of the first Phase 2b clinical study. In October 2024, we received a payment of CHF 24.6 million for triggering the rapid rate of prescreening in the potentially registrational Phase 2b ReTain trial. The Company recognized this income as revenue because we deemed it highly probable that this milestone would be obtained and would not be subject to reversal in the future.

AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Janssen is a customer. The Company identified the following performance obligations under the contract: (i) a right-of-use license and (ii) research and development services including a development and chemistry, manufacturing and controls work plan. The Company considered the research and development capabilities of Janssen, Janssen’s right to sublicense, and the fact that the research and development services are not proprietary and can be provided by other vendors, to conclude that the license has stand-alone functionality and is distinct. The Company’s obligation to perform research and development services does not significantly impact or modify the licenses’ granted functionality. Based on these assessments, the Company identified the license and the research and development services as the performance obligations at the inception of the arrangement, which were deemed to be distinct in the context of the contract.

At execution of the agreement, the transaction price included only the upfront consideration received of CHF 25.9 million. At inception, none of the clinical, regulatory or commercial milestones has been included in the transaction price, as all milestone amounts were fully constrained. As described above, the Company has earned and received various milestone payments related to this contract. In the future, the Company could also receive up to more than CHF 418 million in clinical, regulatory and commercial milestones as well as tiered, low-double digits to mid-teen royalties on aggregate net sales for the ACI-35.030 active immunotherapy program. In assessing that future clinical, regulatory or commercial milestones are fully constrained, the Company considered numerous factors to determine that these milestones are not highly probable to obtain, including that receipt of the milestones is outside the control of the

Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

For the years ended December 31, 2025, 2024 and 2023, we have recognized nil, CHF 24.6 million, and CHF 14.8 million, respectively, from this arrangement.

Tau-PET imaging agent – 2014 agreement with Life Molecular Imaging (LMI)

In May 2014 (as amended in June 2022), we entered into an agreement, our first diagnostic partnership, with LMI, the former Piramal Imaging SA. The partnership with LMI is an exclusive, worldwide licensing agreement for the research, development and commercialization of the Company’s Tau protein PET tracers supporting the early diagnosis and clinical management of AD and other Tau-related disorders and includes upfront and sales milestone payments totaling up to EUR 160 (CHF 150) million, plus royalties on sales at a percentage rate ranging from mid-single digits to low-teens. To date, the Company has received EUR 7.5 million (CHF 7.9 million) of payments related to these milestones and is eligible to receive the remaining EUR 152.5 million (CHF 142.9 million) related to achievement of certain clinical milestones as well as regulatory and sales-based milestones. No payments have been received in 2023, 2024, or 2025.

AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that LMI is a customer. The Company has identified that the right-of-use license as the only performance obligation. The Company determined that transaction price based on the defined terms allocated to each performance obligation specified in the contract.

The upfront payment constitutes the amount of consideration to be included in the transaction price and has been allocated to the license. None of the clinical, regulatory or commercial milestones has been included in the transaction price as these variable consideration elements are considered fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts.

Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to LMI and therefore are recognized at the later of when the performance obligation is satisfied or the related sales occur. The Company considered LMI’s right to sublicense and develop the Tau protein PET tracers, and the fact that LMI could perform the research and development work themselves within the license term without AC Immune, to conclude that the license has stand-alone functionality and is distinct. The Company believes that the contracted amount represents the fair value. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

For the years ended December 31, 2025, 2024 and 2023, the Company has recognized no revenues from this arrangement.

Anti-Abeta Active Immunotherapy in AD – 2024 agreement with Takeda Pharmaceuticals, USA, Inc

In May 2024, the Company entered into a worldwide option and license agreement with Takeda Pharmaceuticals, USA, Inc. (Takeda) for our active immunotherapies targeting Abeta, including ACI-24.060 for the treatment of AD. AC Immune will be responsible for completing the ABATE trial. Following option exercise, Takeda would conduct and fund all further clinical development and be responsible for all global regulatory activities as well as worldwide commercialization. Under the terms of the agreement, AC Immune received an upfront payment of USD 100.0 (CHF 92.3) million in May 2024 and is eligible to receive an option exercise fee in the low-to-mid nine-figure USD range and additional potential development, commercial and sales-based milestones of up to approximately USD 2.1 (CHF 1.7) billion if all related milestones are achieved over the course of the agreement. Upon commercialization, AC Immune will be entitled to receive tiered mid-to-high teens percentages royalties on worldwide net sales.

Under the terms of the agreement, Takeda may terminate the agreement at any time by providing 90 days’ notice to the Company. If not otherwise terminated, the agreement shall continue until Takeda decides not to exercise its license option or until the expiration of all royalty obligations as outlined in the contract.

AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Takeda is a customer. The Company identified the following performance obligations under the contract: (i) a license option and (ii) development, chemistry, manufacturing, and controls (“CMC”) and regulatory activities as outlined in the development and CMC plans, which are necessary to deliver the data package to Takeda. AC Immune concluded that the license option is considered a material right, as the value of the license exceeds the option exercise fee, thereby considering it a distinct performance obligation. The development, CMC, and regulatory activities are treated as one distinct performance obligation because the underlying activities are not distinguishable in the context of the contract and are inputs to an integrated development program that will generate valuable data and information for Takeda in determining whether to exercise the option.

At the agreement's execution, the transaction price included only the upfront and non-refundable consideration of USD 100.0 (CHF 92.3) million. At inception, none of the development milestones, which may occur prior to the Takeda option exercise, were included in the transaction price, as all milestone amounts were fully constrained. The Takeda option exercise payment and any future development and commercial milestone payments, and royalties following the Takeda option exercise were excluded from the initial transaction price at contract inception. The option exercise fee is considered variable consideration as it depends on Takeda's decision to exercise. In assessing that future development or commercial milestones are fully constrained, the Company considered numerous factors, including that the receipt of these milestones is contingent upon success in future clinical trials and the licensee’s efforts, and thus not highly probable to obtain. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur, as they predominantly relate to the license that will be granted to Takeda upon exercise and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved or other changes in circumstances occur.

The valuation of each performance obligation involves estimates and assumptions, with the timing of revenue recognition determined by either delivery or the provision of services. In line with the allocation objective under IFRS 15, the Company allocated the USD 100.0 (CHF 92.3) million upfront payment within the transaction price to the license option and development, CMC, and regulatory activities, using the relative stand-alone selling price method. For the standalone selling price of the license option, the Company utilized an income-based approach, which included key assumptions such as the post-option development timeline and costs, revenue forecasts, discount rates, and probabilities of development and regulatory success. The standalone selling price for the development, CMC and regulatory activities was calculated using a cost-plus margin approach based on the estimated development timeline. The Company allocated the transaction price based on the relative standalone selling prices, assigning USD 87.4 (CHF 80.7) million to the license option and USD 12.6 (CHF 11.6) million to development, CMC, and regulatory activities.

The Company has deferred revenue recognition for the license option and will recognize the entirety of the revenue either when the option is exercised and Takeda obtains the exclusive license, or when the option expires. The Company will recognize revenue related to the development, CMC and regulatory performance obligation over the estimated period of completion of these obligations, using an input method reflecting the costs incurred relative to the total costs expected to be incurred.

For the years ended December 31, 2025, 2024, and 2023, the Company recorded contract revenue of CHF 3.6 million, CHF 2.7 million, and nil, respectively, reflecting its efforts under this agreement.

As of December 31, 2025, the Company recorded CHF 86.0 million in deferred contract revenue related to the unsatisfied performance obligations under this agreement, compared to 89.6 million of December 31, 2024. The deferred contract revenue allocated to the license option is classified as short-term on the consolidated balance sheets because, in accordance with IAS 1, the Company does not have the right to defer the settlement of that portion for at least twelve months after the reporting period. The deferred contract revenue allocated to development, CMC, and regulatory activities will be recognized over the remaining performance period and classified as either current or non-current on the consolidated balance sheets, based on the expected timing of satisfaction of the performance obligations.

13.2 Grant income

Grants from the Michael J. Fox Foundation

In December 2021, the Company announced that it had been awarded two grants totaling USD 1.5 (CHF 1.4) million to advance small molecule PD programs. One award supported an existing early-stage program to develop small molecules that can prevent intracellular aggregation and spreading of a-syn. The other award funded research on the therapeutic potential of chemically and mechanistically novel, brain penetrant small molecule inhibitors of NLRP3 inflammasome activation for the treatment of PD.

In August 2022, the Company received follow-on grant funding as part of its joint arrangement with Skåne in Sweden totaling USD 0.5 (CHF 0.5) million for the continued development of its alpha-synuclein PET imaging diagnostic agent. As part of this grant, AC Immune received USD 0.4 (CHF 0.4) million directly from the MJFF. Skåne received USD 0.1 (CHF 0.1) million of the total grant directly from the MJFF over the duration of the grant period.

In February 2023, the Company announced that it had been awarded a new grant totaling USD 0.5 (CHF 0.4) million from the MJFF to support the development of its TDP-43 PET tracer program.

For the years ended December 31, 2025, the Company has recognized nil, less than CHF 0.1 million for the year ended December 31, 2024 and CHF 1.2 million for the year ended December 31, 2023, from its MJFF grants, under “Other operating income/(expense), net”.

14.Expenses by category

Research and development


	For the Year Ended
	December 31,
In CHF thousands	2025	2024	2023
Operating expenses	33,890	39,177	32,076
Depreciation expense	886	986	1,122
Payroll expenses	20,213	20,195	19,499
Share-based compensation	1,447	2,212	1,909
Total research and development expenses	56,436	62,570	54,606

The decrease of research and development expenses in 2025 compared with the prior period is predominantly driven by decreases in manufacturing costs not recurring in the current period for ACI-7104.056 and reduced activity in the Company’s discovery and preclinical expenses for the TDP-43 antibody and PET tracer programs.

For the years ended December 31, 2025, 2024 and 2023, the Company had 105.0, 122.5 and 115.4 FTEs in our research and development functions.

General and administrative


	For the Year Ended
	December 31,
In CHF thousands	2025	2024	2023
Operating expenses	2,825	4,672	3,658
Depreciation expense	1,617	1,153	1,071
Payroll expenses	8,529	8,222	7,755
Share-based compensation	3,123	3,212	2,821
Total general and administrative expenses	16,094	17,259	15,305

In 2025, general and administrative expenses decreased compared to the previous year, primarily driven by a decrease in legal fees related to business development and licensing activities, as well as lower salaries and related costs as a result of the restructuring, partly offset by increased severance costs.

For the years ended December 31, 2025, 2024 and 2023, the Company had 26.7, 30.9 and 26.2 FTEs in our general and administrative functions.

Financial result, net


	For the Year Ended
	December 31,
In CHF thousands	2025	2024	2023
Financial income	1,865	3,196	1,044
Financial expense	(191)	(133)	(176)
Exchange differences	(2,803)	(1,598)	(1,467)
Finance result, net	(1,129)	1,465	(599)

Our finance result primarily consists of interest income associated with our short-term financial assets and interest expense associated with lease liabilities as well as foreign currency exchange differences.

For the year ended December 31, 2025, the unfavorable change in net finance result of CHF 2.5 million primarily related to a decrease of CHF 1.3 million in financial income attributed to lower interest received on net investments in short-term financial assets, with less deposits made in 2025 compared to the previous period. The unfavorable change in exchange differences was caused by foreign currencies depreciating against the Swiss franc, predominantly the U.S. Dollar.

15.Related-party transactions

Board of directors and executive management compensation

Key management includes the board of directors and executive management. For 2025, there were six members (2024: six members and 2023: eight) of the Board (excluding the CEO) and three members (2024: seven and 2023: seven) of executive management (including the CEO). Compensation was as follows:


	For the Year Ended
	December 31,
In CHF thousands	2025	2024	2023
Short-term employee benefits	3,533	5,071	4,661
Post-employment benefits	418	476	446
Share-based compensation	3,051	3,571	3,251
Total compensation	7,002	9,118	8,358

16.Income taxes

The Group recognized less than CHF 0.1 million in income taxes and no deferred tax asset or liability positions for the years ended December 31, 2025, 2024 and 2023, respectively. The Group’s expected tax expense for each year is based on the applicable tax rates in each jurisdiction. In 2025, these rates ranged from 13.6% to 34.0% (13.6% - 33.8% for 2024 and 2023) in the Group’s respective tax jurisdictions. The weighted average tax rate applicable to the Group was 13.6% (13.6% for 2024 and 2023, respectively).

The Group’s income tax expense for each year can be reconciled to loss before tax as follows:


	For the Year Ended
	December 31,
In CHF thousands	2025	2024	2023
Loss before income tax	(70,447)	(50,913)	(54,223)
Tax benefit calculated at the domestic rates applicable in the respective countries	(9,586)	(6,925)	(7,371)
(Income not subject to tax)/expenses not deductible for tax purposes	598	692	611
Effect of unused tax losses and tax offsets not recognized as deferred tax assets	8,988	6,236	6,770
Effective income tax rate expense	—	3	10

The Swiss tax rate used for the 2025 reconciliations is the corporate tax rate of 13.6% (13.6% in 2024 and 2023, respectively) payable by corporate entities in the Canton of Vaud, Switzerland on taxable profits under tax law in that jurisdiction.

The below table details the total unrecognized deductible temporary differences, unused tax losses and unused tax credits:


	As of
	December 31,
In CHF thousands	2025	2024
Unrecognized deductible temporary differences, unused tax losses and unused tax credits
Deductible temporary differences, unused tax losses and unused tax credits for which no deferred tax assets have been recognized are attributable to the following:
Tax losses	362,290	343,589
Deductible temporary differences related to:
Retirement benefit plan	8,645	8,844
Total	370,935	352,433

The following table details the tax losses carry forwards of the Company and their respective expiry dates:


	As of
	December 31,
In CHF thousands	2025	2024
Tax losses split by expiry date:
December 31, 2025	—	48,894
December 31, 2026	—	—
December 31, 2027	57,824	57,824
December 31, 2028	75,204	75,204
December 31, 2029	66,936	66,936
December 31, 2030	48,883	48,883
December 31, 2031	45,848	45,848
December 31, 2032	67,595	—
Total unrecorded tax loss carryforwards	362,290	343,589

The tax losses available for future offset against taxable profits have increased by CHF 18.7 million from 2024, representing the amount of tax losses that are additionally available as an offset reduced by expiring tax losses in 2025 of CHF 48.9 million, subject to expiration as disclosed in the table above, against future taxable income.

Consistent with prior years, the Company has not recorded any deferred tax assets in relation to the past tax losses available for offset against future profits as the recognition criteria were not met at the balance sheet date.

17.Retirement benefit plan

The Company participates in a collective foundation covering all of its employees including its executive officers. In addition to retirement benefits, the plan provides death or long-term disability benefits.

Contributions paid to the plan are computed as a percentage of salary, adjusted for the age of the employee and shared approximately 47% and 53% by employee and employer, respectively.

This plan is governed by the Swiss Law on Occupational Retirement, Survivors and Disability Pension Plans (BVG), which requires contributions to be made to a separately administered fund. The fund has the legal form of a foundation and it is governed by a board of trustees, which consists of an equal number of employer and employee representatives of its members. The board of trustees is responsible for the administration of the plan assets and for the definition of the investment strategy. The Company has no direct influence on the investment strategy of the foundation board.

The assets are invested by the pension plan, to which many companies contribute, in a diversified portfolio that respects the requirements of the Swiss BVG. Therefore, disaggregation of the pension assets and presentation of plan assets in classes that distinguish the nature and risks of those assets is not possible. Under the plan, both the Company and the employee share the costs. The structure of the plan and the legal provisions of the BVG mean that the employer is exposed to actuarial risks. The main risks are investment risk, interest risk, disability risk and the life expectancy of pensioners. Through our affiliation with the pension plan, the Company has minimized these risks, as they are shared between a much greater number of participants. On leaving the Company, a departing employee’s retirement savings are transferred to the pension institution of the new employer or to a vested benefits institution. This transfer mechanism may result in pension payments varying considerably from year to year.

The pension plan is exposed to Swiss inflation, interest rate risks and changes in the life expectancy for pensioners. For accounting purposes under IFRS Accounting Standards, the plan is treated as a defined benefit plan in accordance with IAS 19.

The following table sets forth the status of the defined benefit pension plan and the amount that is recognized in the consolidated balance sheets:


	As of
	December 31,
In CHF thousands	2025	2024	2023
Defined benefit obligation	(48,261)	(52,455)	(41,060)
Fair value of plan assets	39,615	43,611	35,290
Total liability	(8,646)	(8,844)	(5,770)

The following amounts have been recorded as net pension cost in the consolidated statements of income/(loss):


	For the Year Ended
	December 31,
In CHF thousands	2025	2024	2023
Current service cost	1,952	1,688	1,453
Past service cost	—	—	903
(Gains) and losses on settlement / curtailment	(1,757)	—	—
Interest cost	544	680	804
Interest income	(438)	(574)	(705)
Net pension cost	301	1,794	2,455

The changes in defined benefit obligation, fair value of plan assets and unrecognized gains/(losses) are as follows.

A. Change in defined benefit obligation


	For the Year Ended
	December 31,
In CHF thousands	2025	2024	2023
Defined benefit obligation as of January 1	(52,455)	(41,060)	(32,410)
Current service cost	(1,952)	(1,688)	(1,453)
Past service cost	—	—	(903)
Interest cost	(544)	(680)	(804)
Change in demographic assumptions	—	(16)	136
Change in financial assumptions	(2,652)	(3,846)	(2,908)
Change in experience assumptions	831	(1,078)	(57)
Benefits (deposited)/paid	4,119	(2,504)	(1,265)
Gains and (losses) on settlement / curtailment	6,057	—	—
Employees’ contributions	(1,665)	(1,583)	(1,396)
Defined benefit obligation as of December 31	(48,261)	(52,455)	(41,060)

B.Change in fair value of plan assets


	For the Year Ended
	December 31,
In CHF thousands	2025	2024	2023
Fair value of plan assets as of January 1	43,611	35,290	29,197
Interest income	438	574	705
Employees’ contributions	1,665	1,583	1,396
Employer’s contributions	1,853	1,804	1,567
Benefits (paid) / deposited	(4,119)	2,504	1,265
Gains and (losses) on settlement / curtailment	(4,300)	—	—
Return on plan assets excluding interest income	467	1,856	1,160
Fair value of plan assets as of December 31	39,615	43,611	35,290

Expected contributions by the employer to be paid to the post-employment benefit plans during the annual period beginning after the end of the reporting period amount to approximately CHF 1.5 million.

C.Change in net defined benefit liability


	For the Year Ended
	December 31,
In CHF thousands	2025	2024	2023
Net defined benefit liabilities as of January 1	8,844	5,770	3,213
Net pension cost through statement of income/(loss)	301	1,794	2,455
Remeasurement through other comprehensive income/(loss)	1,353	3,084	1,669
Employer’s contribution	(1,853)	(1,804)	(1,567)
Net defined benefit liabilities as of December 31	8,645	8,844	5,770

D.Other comprehensive gains/(losses)


	For the Year Ended
	December 31,
In CHF thousands	2025	2024	2023
Effect of changes in demographic assumptions	—	(16)	136
Effect of changes in financial assumptions	(2,652)	(3,846)	(2,908)
Effect of changes in experience assumptions	831	(1,078)	(57)
Return on plan assets excluding interest income	467	1,856	1,160
Total other comprehensive gain/(loss)	(1,353)	(3,084)	(1,669)

In 2024, the change in experience assumptions mainly due to new active insured and pensioners. In 2025, the change in experience assumptions is mainly due to leavers after the restructuring. The experience changes are offset by an increase in the interest rate on savings capital which was updated based on emerging long-term trends of increased returns on capital.

The fair value of the plan assets is the cash surrender value of the insurance with the insurance company (AXA). The investment strategy defined by the board of trustees follows a conservative profile.

The weighted-average duration of the defined benefit obligation is 16.1 years and 16.3 years as of December 31, 2025 and 2024, respectively.

The actuarial assumptions used for the calculation of the pension cost and the defined benefit obligation of the defined benefit pension plan for the years ended December 31, 2025, 2024 and 2023, respectively, are as follows:


	For the Year Ended
	December 31,
	2025		2024		2023
Discount rate	1.30	%	1.00	%	1.50	%
Rate of future increase in compensations	2.00	%	2.00	%	1.75	%
Rate of future increase in current pensions	0.00	%	0.00	%	0.00	%
Interest rate on retirement savings capital	3.25	%	1.25	%	1.50	%
Mortality and disability rates	2020 GT (CMI)		BVG 2020 GT (CMI)		BVG 2020 GT (CMI)

In defining the benefits, the minimum requirements of the Swiss BVG and its implementing provisions must be observed. The BVG defines the minimum pensionable salary and the minimum retirement credits.

A quantitative sensitivity analysis for significant assumptions as of December 31, 2025 is shown below:

Interest rate on

Discount rate

Future salary increase

Future pension cost

savings capital

0.5%

Assumptions

increase

decrease

increase

decrease

increase

decrease

increase

decrease

In CHF thousands

Potential defined benefit obligation

44,698

52,332

49,343

47,256

50,262

46,435

49,613

46,984

Decrease/(increase) from actual defined benefit obligation

3,563

(4,071)

(1,082)

1,005

(2,001)

1,826

(1,352)

1,277

A quantitative sensitivity analysis for significant assumptions as of December 31, 2024 is shown below:

Interest rate on

Discount rate

Future salary increase

Future pension cost

savings capital

0.5%

Assumptions

increase

decrease

increase

decrease

increase

decrease

increase

decrease

In CHF thousands

Potential defined benefit obligation

48,532

56,936

53,728

51,262

54,683

50,423

53,865

51,118

Decrease/(increase) from actual defined benefit obligation

3,923

(4,481)

(1,273)

1,193

(2,228)

2,032

(1,410)

1,337

The sensitivity analyses above are subject to limitations and have been determined based on a method that extrapolates the impact on net defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period.

18.Share-based compensation

Share-based option awards

As of December 31, 2025, there are equity-based instruments outstanding that the Company has granted under two different plans.

The Company’s 2016 Share Option and Incentive Plan (SOIP) was approved by the shareholders at the ordinary shareholders’ meeting in November 2016. The 2016 Plan authorizes the grant of incentive and non-qualified share options, share appreciation rights, restricted share awards, restricted share units, unrestricted share awards, performance share awards, performance-based awards to covered employees and dividend equivalent rights. The Company only grants equity-based instruments from the SOIP as of December 31, 2025.

The following table summarizes equity-settled share option grants for plans that existed during the period:


		Number of
		options awarded				Contractual
Plan		(since inception)		Vesting conditions		life of options
Share option plan C1		6,775,250		4 years’ service from grant date		10 years
2016 SOIP:
Executives and directors		5,869,455		1 year, 3 year and 4 years’ service from the date of grant, quarterly and annually		10 years
Employees		1,888,258		4 years’ service from the date of grant, annually		10 years

The number and weighted-average exercise prices (in CHF) of options under the share option programs for Plans C1 and the 2016 SOIP are as follows:


				Weighted-		Weighted-
				average		average
		Number of		exercise price		remaining
		options		(CHF)		term (years)
Outstanding at January 1, 2023		4,261,017		5.65		7.6
Forfeited during the year		(824,084)		5.34		—
Exercised during the year		(42,037)		1.52		—
Granted during the year		1,554,281		1.75		—
Outstanding at December 31, 2023		4,949,177		4.11		7.2
Exercisable at December 31, 2023		3,022,345		4.88		6.4
Outstanding at January 1, 2024		4,949,177		4.11		7.2
Forfeited during the year		(135,118)		3.28		—
Expired during the year		(205,634)		5.41
Exercised during the year		(4,278)		3.11		—
Granted during the year		406,680		3.40		—
Outstanding at December 31, 2024		5,010,827		4.50		6.3
Exercisable at December 31, 2024		4,097,932		4.79		5.9
Outstanding at January 1, 2025		5,010,827		4.50		6.3
Forfeited during the year		(69,422)		3.46		—
Expired during the year		(89,722)		3.77		—
Exercised during the year		(41,140)		0.23		—
Granted during the year		708,021		2.09		—
Outstanding at December 31, 2025		5,518,564		4.25		5.9
Exercisable at December 31, 2025		4,815,928		4.54		5.5

The outstanding stock options as of December 31, 2025 have the following range of exercise prices:


				Weighted-
				average
				remaining
		Total options		term (years)
Range of exercise prices
CHF 0.15		15,625		0.40
CHF 9.53		109,665		1.50
USD 2.03 to USD 3.00		2,031,586		7.65
USD 3.00 to USD 6.00		1,885,863		5.43
USD 6.00 to USD 9.00		1,356,455		4.54
USD 9.00 to USD 12.30		119,370		2.06
Total outstanding options		5,518,564

The weighted-average exercise price for options granted in 2025, 2024 and 2023 is USD 2.40 (CHF 2.09), USD 3.99 (CHF 3.40) and USD 2.08 (CHF 1.75), respectively. The range of exercise prices for outstanding options was CHF 0.15 to CHF 9.53 for awards previously granted in CHF (prior to 2018) and USD 1.84 to USD 12.30 for awards granted in USD as of December 31, 2025.

For awards issued in 2024, the volatility is based on the Company’s actual volatility for the period congruent with the expected term of the underlying option. The risk-free interest rate is based on yields of long-dated U.S. Treasury notes that align with the expected term of the award. The weighted-average share price of common share options exercised in 2025 is USD 2.57 (CHF 2.12).

The weighted-average grant date fair values of the options granted in 2025, 2024 and 2023 are USD 1.69 (CHF 1.47), USD 3.68 (CHF 3.13) and USD 1.57 (CHF 1.33), respectively. The following table illustrates the weighted-average assumptions for the Black-Scholes option-pricing model used in determining the fair value of these awards:


	For the Year Ended
	December 31,
	2025		2024		2023
Exercise price (USD)	1.84-2.91		3.39-4.23		2.03-3.11
Share price (USD and weighted average)	2.40		3.99		2.08
Risk-free interest rate	4.2-4.5	%	3.7-4.2	%	4.0-4.6	%
Expected volatility	56-85	%	82-107	%	72-86	%
Expected term (in years)	6.25-8.25		5.5-6		5.5-6
Dividend yield	—		—		—

Restricted share awards

A summary of share awards (restricted share and restricted share units) activity as of December 31, 2025 and changes during the year then ended is presented below:


						Contractual
		Number of				life of non-
		share awards granted				vested share
Grantee type		(since inception)		Vesting conditions		awards
Restricted share units
Directors		431,875		1 year and 3 years' service from date of grant, annually		10 years
Executives		2,189,707		1 year and 3 years' service from the date of grant, quarterly		10 years
Employees		1,571,569		3 years’ service from the date of grant, annually		10 years


				Weighted-
				average
		Number of		grant date fair
		shares		value (CHF)
Non-vested at January 1, 2023		216,486		3.06
Forfeited during the year		(134,947)		2.05
Exercised during the year		(55,503)		2.37
Granted during the year		1,187,570		1.89
Vested during the year		(265,366)		2.46
Non-vested at December 31, 2023		1,003,743		1.97
Vested and exercisable at December 31, 2023		298,883		4.08
Non-vested at December 31, 2023		1,003,743		1.97
Forfeited during the year		(97,841)		3.26
Exercised during the year		(99,018)		2.54
Granted during the year		1,094,876		4.04
Vested during the year		(1,064,554)		3.05
Non-vested at December 31, 2024		822,740		3.12
Vested and exercisable at December 31, 2024		1,377,903		3.25
Non-vested at December 31, 2024		822,740		3.12
Forfeited during the year		(176,609)		3.16
Exercised during the year		(127,537)		2.96
Cancelled during the year		(34,612)		2.04
Granted during the year		1,477,623		2.34
Vested during the year		(1,309,210)		2.55
Non-vested at December 31, 2025		763,816		2.62
Vested and exercisable at December 31, 2025		2,575,692		2.91

The weighted-average grant date fair values of the remaining non-vested share awards as of the respective year end for the restricted share units were CHF 2.62, CHF 3.12 and CHF 1.97 for the years ended December 31, 2025, 2024 and 2023, respectively. The fair values of these non-vested share awards granted were determined using the market value of the common shares on the date of the award.

The expense charged against the income statement related to all share-based compensation was CHF 4.4 million, CHF 5.5 million and CHF 4.4 million for the years ended December 31, 2025, 2024 and 2023, respectively. The expense is determined by the Company based on the number of instruments that are expected to become exercisable.

19.Commitments and contingencies

The Company’s commitments and contingencies relate to its ongoing operating activities, mainly research and development programs, as well as its leased corporate space.

In the normal course of business, we conduct product research and development programs through collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. We have contractual arrangements with these organizations.

We lease our corporate, laboratory and other facilities under multiple leases at the EPFL Innovation Park in Ecublens, near Lausanne, Canton of Vaud, Switzerland. Our lease agreements have no termination clauses longer than a 12-month contractual notice period. The Company recognizes a right-of-use asset for its leases, except for short-term and low-value leases as indicated in Note 3. See “Note 5. Right-of-use assets, long-term financial assets and lease liabilities” for the contractual undiscounted cash flows for lease obligations. The below table represents contractual

commitments excluding capitalized leases which are recorded on the balance sheet, the related future cash flows are presented in Note 5.


	As of
	December 31,
In CHF thousands	2025	2024
Within 1 year	23,357	27,554
Between 1 and 3 years	21,865	11,652
Between 3 and 5 years	7,178	4,008
More than 5 years	144	65
Total	52,544	43,279

20.Earnings per share


	For the Year Ended
	December 31,
In CHF thousands except for share and per share data	2025	2024	2023
Loss per share (EPS)
Numerator
Net loss attributable to equity holders of the Company	(70,447)	(50,916)	(54,233)
Denominator
Weighted-average number of shares outstanding used to compute EPS basic and diluted attributable to equity holders	100,751,705	99,691,971	84,694,616
Basic and diluted loss per share for the period attributable to equity holders	(0.70)	(0.51)	(0.64)

In periods for which we have a loss, basic net loss per share is the same as diluted net loss per share. We have excluded from our calculation of diluted loss per share all potentially dilutive in-the-money (i) share options and (ii) non-vested restricted share awards. See “Note 18. Share-based compensation” for the potentially dilutive equity awards.

21.Financial instruments and risk management

The Company’s activities expose it to the following financial risks: market risk (foreign exchange and interest rate risk), credit risk and liquidity risk. The Company’s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Company’s financial performance.

The following table shows the carrying amounts of financial assets and financial liabilities:


	As of
	December 31,
In CHF thousands	2025	2024
Financial assets
Long-term financial assets	584	415
Other current receivables	978	1,104
Short-term financial assets	64,617	129,214
Cash and cash equivalents	26,795	36,275
Total financial assets	92,974	167,008


	As of
	December 31,
In CHF thousands	2025	2024
Financial liabilities
Long-term lease liabilities	3,689	4,401
Trade and other payables	2,068	2,658
Accrued expenses	8,067	12,098
Short-term lease liabilities	852	1,026
Total financial liabilities	14,676	20,183

Foreign exchange risk

The Company is exposed to foreign exchange risk arising from currency exposures, primarily with respect to the EUR, USD and to a lesser extent to GBP, DKK and SEK. The currency exposure is not hedged. However, the Company has a policy of matching its cash holdings to the currency structure of its expenses, which means that the Company holds predominately CHF, with lesser balances of EUR and USD (see “Note 7. Cash and cash equivalents and short-term financial assets”). The Company recognized a loss of CHF 2.8 million, a loss of CHF 1.6 million and a loss of CHF 1.5 million for the years ended December 31, 2025, 2024 and 2023, respectively, within “Finance result, net.”

As of December 31, 2025, if the CHF had strengthened/weakened by 10% against the EUR and the USD with all other variables held constant, the net loss for the period would have been lower/higher by CHF 3.3 million (2024: CHF 5.0 million), mainly as a result of foreign exchange gains/losses on predominantly EUR/USD denominated cash and cash equivalents and short-term financial assets.

Interest rates

The Company’s CHF cash holdings (inclusive of those held in short-term financial assets) were subject to positive interest rates at certain counterparty thresholds through 2025. As of December 31, 2025 if the interest rates granted by the counterparties had increased/decreased by 10%, the net income for the period would have been higher/lower by CHF 0.1 million. Interest income and interest expense are recorded within finance results, net in our consolidated statements of income/(loss).

Credit risk

The Company maintains a formal treasury risk and investment management policy to limit counterparty credit risk. As of December 31, 2025, the Company’s cash and cash equivalents and short-term financial assets are held with six financial institutions, each with a high credit rating ranging from A+ to AA- assigned by international credit-rating agencies. The maximum amount of credit risk is the carrying amount of the financial assets. Other receivables are fully performing, not past due and not impaired (see “Note 7. Cash and cash equivalents and short-term financial assets” and “Note 10. Other current receivables”).

Liquidity risk

Inherent in the Company’s business are various risks and uncertainties, including the high uncertainty that new therapeutic concepts will succeed. AC Immune’s success may depend in part upon its ability to (i) establish and maintain a strong patent position and protection, (ii) enter into collaborations with partners in the pharmaceutical and biopharmaceutical industries, (iii) acquire and keep key personnel employed and (iv) acquire additional capital to support its operations.

The Company’s approach of managing liquidity is to ensure sufficient cash to meet its liabilities when due. Therefore, management closely monitors the cash position on rolling forecasts based on expected cash flow to enable the Company to finance its operations for at least 12 months. The Company has CHF 2.1 million (CHF 2.7 million in prior

year) in trade and other payables, and CHF 8.1 million (CHF 12.1 million in prior year) in accrued expenses which are due within 12 months from the reporting date. Finally, as it relates to the Company’s lease liabilities please see “Note 5. Right-of-use assets, long-term financial assets and lease liabilities” for detail of when corresponding lease liabilities are due.

22.Capital risk management

The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going concern and to preserve the capital on the required statutory level in order to succeed in developing a cure against (i) AD, (ii) focused non-Alzheimer’s neurodegenerative diseases including NeuroOrphan indications and (iii) diagnostics.

23.Subsequent events

Management has evaluated subsequent events after the balance sheet date, through the issuance of these consolidated financial statements, for appropriate accounting and disclosures. The Company has determined that there were no other such events that warrant disclosure or recognition in these consolidated financial statements.

Table of Contents

Statutory Financial Statements (Swiss CO)

December 31, 2025


	Report of the statutory auditor				2
	Statutory Balance Sheets				9
	Statutory Income Statements				10
	Notes to the Statutory Financial Statements Proposed Carry Forward of the Accumulated Losses				11 23

AC Immune SA

EPFL Innovation Park

1015 Lausanne / Ecublens

Switzerland

Statutory Financial Statements

Table of Contents

Report of the statutory auditor to the General Meeting of AC Immune SA, Ecublens

Report on the audit of the financial statements

Opinion

We have audited the financial statements of AC Immune SA (the Company), which comprise the statutory balance sheet as at December 31, 2025, and the statutory income statement for the year then ended, and notes to the statutory financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements comply with Swiss law and the Company’s articles of incorporation.

Basis for opinion

We conducted our audit in accordance with Swiss law and Swiss Standards on Auditing (SA-CH). Our responsibilities under those provisions and standards are further described in the 'Auditor’s responsibilities for the audit of the financial statements' section of our report. We are independent of the Company in accordance with the provisions of Swiss law and the requirements of the Swiss audit profession that are relevant to audits of the financial statements of public interest entities. We have also fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Statutory Financial Statements

Table of Contents

Our audit approach

Overview

Overall materiality: CHF 2,705 thousand

We tailored the scope of our audit in order to perform sufficient work to enable us to provide an opinion on the financial statements as a whole, taking into account the structure of the Company, the accounting processes and controls, and the industry in which the Company operates.

As key audit matter the following area of focus has been identified:

Intangible asset - valuation

Materiality

The scope of our audit was influenced by our application of materiality. Our audit opinion aims to provide reasonable assurance that the financial statements are free from material misstatement. Misstatements may arise due to fraud or error. They are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

Based on our professional judgement, we determined certain quantitative thresholds for materiality, including the overall materiality for the financial statements as a whole as set out in the table below. These, together with qualitative considerations, helped us to determine the scope of our audit and the nature, timing and extent of our audit procedures and to evaluate the effect of misstatements, both individually and in aggregate, on the financial statements as a whole.



Overall materiality	CHF 2,705 thousand

Benchmark applied	3 years average loss before tax

Rationale for the materiality benchmark applied	Based on our analysis and professional judgement we determined an average of 3 years of loss before tax is the most appropriate benchmark. We chose the average of 3 years of loss before tax because it is the benchmark against which the performance of the Company is most commonly measured, and it is a generally accepted benchmark. In addition, in our view, the selected materiality threshold is aligned with investors and Audit & Finance Committee expectations.

Statutory Financial Statements

Table of Contents

We agreed with the Audit & Finance Committee that we would report to them misstatements above CHF 270 thousand identified during our audit as well as any misstatements below that amount which, in our view, warranted reporting for qualitative reasons.

Audit scope

We designed our audit by determining materiality and assessing the risks of material misstatement in the financial statements. In particular, we considered where subjective judgements were made; for example, in respect of significant accounting estimates that involved making assumptions and considering future events that are inherently uncertain. As in all of our audits, we also addressed the risk of management override of internal controls, including among other matters consideration of whether there was evidence of bias that represented a risk of material misstatement due to fraud.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Intangible asset - valuation



Key audit matter	How our audit addressed the key audit matter

As described in Notes 2 and 4 to the financial statements, the Company has CHF 50,416 thousand of an in-process research and development (IPR&D) intangible asset as of December 31, 2025. The IPR&D asset is reviewed at least annually for impairment by assessing the fair value less costs to sell (recoverable amount) and comparing this to the carrying value of the asset. The significant assumptions used in the valuation model in accordance with an income approach to determine the recoverable amount include observable and unobservable key inputs as follows: anticipated research and development costs, anticipated costs of goods and sales and marketing expenditures, probability of achieving clinical and regulatory development milestones in accordance with certain industry benchmarks, target indication prevalence and incidence rates, anticipated market	Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. These procedures included testing the effectiveness of controls relating to management’s valuation of the intangible asset. These procedures also included, among others, (i) testing management’s process for developing the fair value estimate; (ii) evaluating the appropriateness of the discounted cash flow model; (iii) testing the completeness and accuracy of underlying data used in the model; and (iv) evaluating the reasonableness of the significant assumptions used by management related to anticipated research and development costs, anticipated costs of goods and sales and marketing expenditures, probability of achieving clinical and regulatory development milestones in

Statutory Financial Statements

Table of Contents

share, general commercialization expectations such as anticipated pricing and uptake, expected patent life and market exclusivity periods, and the discount rate used to discount future cash flows. The Company’s valuation model calculates the risk-adjusted, net cash flows through the period of market exclusivity across target sales regions.

The principal considerations for our determination that performing procedures relating to the intangible asset – valuation is a key audit matter are (i) the significant judgment by management when determining the value of the intangible asset; (ii) a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating the audit evidence obtained related to the valuation of the intangible asset and management’s assumptions related to anticipated research and development costs, anticipated costs of goods and sales and marketing expenditures, probability of achieving clinical and regulatory development milestones in accordance with certain industry benchmarks, target indication prevalence and incidence rates, anticipated market share, general commercialization expectations such as anticipated pricing and uptake, expected patent life and market exclusivity periods, and the discount rate used to discount future cash flows.; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.

accordance with certain industry benchmarks, target indication prevalence and incidence rates, anticipated market share, general commercialization expectations such as anticipated pricing and uptake, expected patent life and market exclusivity periods, and the discount rate. Evaluating management’s assumptions related to anticipated research and development costs, anticipated costs of goods and sales and marketing expenditures, probability of achieving clinical and regulatory development milestones in accordance with certain industry benchmarks, target indication prevalence and incidence rates, anticipated market share, general commercialization expectations such as anticipated pricing and uptake, expected patent life and market exclusivity periods, involved evaluating whether the assumptions used by management were reasonable considering (i) the consistency with market and industry data; and (ii) whether these assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in the evaluation of the Company’s discounted cash flow model and the discount rate assumption.

Other information

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Statutory Financial Statements

Table of Contents

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Board of Directors’ responsibilities for the financial statements

The Board of Directors is responsible for the preparation of financial statements in accordance with the provisions of Swiss law and the Company’s articles of incorporation, and for such internal control as the Board of Directors determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Swiss law and SA-CH will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Swiss law and SA-CH, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

●

Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

●	Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control.

●	Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made.

Statutory Financial Statements

Table of Contents

●

Conclude on the appropriateness of the Board of Directors’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Company to cease to continue as a going concern.

From the matters communicated with the Board of Directors or its relevant committee, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor’s report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other legal and regulatory requirements

Based on our audit according to article 728a para. 1 item 2 CO, we confirm that the Board of Directors' proposal complies with Swiss law and the Company’s articles of incorporation. We recommend that the financial statements submitted to you be approved.

Statutory Financial Statements

Table of Contents

PricewaterhouseCoopers SA

/s/ Alex Fuhrer	/s/ Thomas Kohler
Licensed audit expert	Licensed audit expert
Auditor in charge

Lausanne, March 13, 2026

Statutory Financial Statements

Table of Contents

AC Immune SA, Ecublens

Statutory Balance Sheets


			As of December 31,
In CHF thousands		Note	2025		2024

Assets

Current assets
Cash and cash equivalents		6	26,781		36,260
Short-term financial assets		6	64,617		129,214
Other current receivables
- From third parties		7	928		1,056
- Intercompany		7	—		4
Prepaid expenses		8	3,972		4,301
Accrued income		9	360		1,099
Total current assets			96,658		171,934

Non-current assets
Long-term financial assets		5	585		415
Property, plant and equipment		3	1,989		2,651
Intangible assets		4	50,416		50,416
Total non-current assets			52,990		53,482

Total assets			149,648		225,416

Liabilities and shareholders’ equity

Current liabilities
Trade payables
- To third parties		10	2,063		2,658
- Intercompany		10	3		—
Accrued expenses		10/11	7,520		11,788
Short-term deferred contract revenue		12	83,706		85,056
Total current liabilities			93,292		99,502

Non-current liabilities
Long-term deferred contract revenue		12	2,339		4,560
Total non-current liabilities			2,339		4,560

Shareholders’ equity
Share capital		13	2,202		2,199
Reserves from capital contributions			476,474		476,219
Accumulated losses brought forward			(356,846)		(310,998)
Treasury shares		14	(218)		(218)
Loss for the year			(67,595)		(45,848)
Total shareholders’ equity			54,017		121,354

Total liabilities and shareholders’ equity			149,648		225,416

Statutory Financial Statements

Table of Contents

AC Immune SA, Ecublens

Statutory Income Statements


		For the Year Ended
		December 31,
In CHF thousands	Note	2025		2024

Revenue	15	3,977		28,568

Operating expenses
Salaries and related costs	16	(28,789)		(28,716)
Operating expenses	16	(38,322)		(45,796)
Depreciation of fixed assets	16	(1,378)		(1,485)
Restructuring expenses	11	(2,129)		—
Total operating expenses		(70,618)		(75,997)

Operating loss		(66,641)		(47,429)

Financial income	17	1,865		3,196
Financial expenses	17	(2,819)		(1,615)
Total financial result, net		(954)		1,581
Loss for the period		(67,595)		(45,848)

Statutory Financial Statements

Table of Contents

AC Immune SA, Ecublens

Notes to the statutory financial statements

1.	General information

AC Immune SA (“AC Immune,” “the Company,” “we”) is a clinical-stage biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel proprietary medicines and diagnostics for prevention and treatment of neurodegenerative diseases (NDD) associated with protein misfolding. Misfolded proteins are generally recognized as the leading cause of NDD, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), with common mechanisms and drug targets, such as amyloid beta (Abeta), Tau, alpha-synuclein (a-syn) and TDP-43. . Our goal is to continue leveraging our proprietary discovery platforms, SupraAntigen and Morphomer, to shift the treatment paradigm for neurodegenerative disease towards Precision Medicine. Our corporate strategy is focused on two core value drivers: (i) Active Immunotherapies being developed for the treatment and prevention of Alzheimer’s disease (AD) and Parkinson’s disease (PD); and (ii) Intracellular targeting with brain penetrant small molecule programs targeting intracellular pathologies.

The Company was initially incorporated as a limited liability company on February 13, 2003 in Basel and effective August 25, 2003 was transitioned into a stock company. The Company’s corporate headquarters are located at EPFL Innovation Park Building B, 1015 Lausanne, Switzerland.

The statutory financial statements of AC Immune for the period ended December 31, 2025 were authorized for issue in accordance with a resolution of the Board of Directors on March 11, 2026 and will be submitted to the next Ordinary General Assembly.

During 2025 and 2024, AC Immune had an annual average of more than 10 but less than 250 full time equivalent positions.

Where necessary, comparative figures have been adjusted to conform with changes in presentation in the current year.

2.	Summary of significant accounting principles

The present annual accounts have been prepared in accordance with the provisions of the Swiss law on accounting and financial reporting (32^ndTitle of the Swiss Code of Obligations). The principal accounting policies are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Current vs. non-current classification

The Company presents assets and liabilities in the balance sheets based on a current/non-current classification. The Company classifies as current all amounts (assets) that are to be realized within 12 months after the reporting period and classifies as non-current all other amounts (assets). For liabilities, any amounts expected to be settled within 12 months after the reporting period are classified as current if the Company does not have the right to defer settlement for at least 12 months after the reporting period - all other amounts (liabilities) are classified as non-current.

Foreign currency transactions

The financial statements are presented in Swiss Francs (CHF). Foreign currency transactions are translated into the functional currency (CHF) using prevailing exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into CHF at rates of exchange prevailing at the reporting date. Any gains or losses from these translations are included in the income statement in the period in which they arise.

Non-monetary assets and liabilities at historical costs are converted at the foreign exchange rate at the time of the transaction. Any foreign exchange profits are deferred in the balance sheet as not having an effect on net income. Foreign exchange losses, on the other hand, are recorded in the profit and loss account.

Statutory Financial Statements

Table of Contents

AC Immune SA, Ecublens

Revenue recognition

Revenue includes upfront fees, milestone payments as well as revenue from research and development agreements associated with collaborations with third parties and grants from public institutions and foundations.

License of intellectual property

Revenue from non-refundable, upfront license payments and performance milestones where the Company has continuing involvement is recognized over the estimated performance or agreement period, depending on the terms of the agreement. The recognition of revenue is prospectively changed for subsequent changes in the development or agreement period.

For collaboration agreements on product candidates (i) that are in clinical development, (ii) where the upfront payment reflects a payment for past investments the Company has made in the development of the product candidate, access to the product candidate, the associated intellectual property and our knowledge, and, (iii) where there is no further performance commitment, the Company recognizes the fair value of the upfront payment at the time of entering into the collaboration agreement. For collaboration agreements (i) in clinical development but where conditions (ii) and (iii) are not met, the Company recognizes revenue from upfront payments under our collaboration agreements when the performance obligations are satisfied.

For collaboration agreements, in addition to receiving upfront payments, the Company is also entitled to milestone and other contingent payments upon achieving pre-defined objectives.

Milestone payments

Revenue from milestones, if they are non-refundable and deemed substantive, is recognized upon successful accomplishment of the milestones. To the extent that non-substantive milestones are achieved, and the Company has remaining performance obligations, milestones are deferred and recognized as revenue over the estimated remaining period of performance.

Research and development services

The Company has certain arrangements with our collaboration partners that include contracting our full-time employees for research and development programs. These revenues are recorded in license and collaboration revenues as the services are performed.

Grant income

The Company has received grants, from time to time from institutions to support certain research projects. Grants are recorded in the income statement within Revenue when there is reasonable assurance that the Company will satisfy the underlying grant conditions and the grants will be received. In certain circumstances, grant income may be recognized before formal grantor acknowledgement of milestone achievements. To the extent required, grant income is deferred and recognized on a systematic basis over the periods in which the Company expects to recognize the related expenses for which the grants are intended to compensate.

Statutory Financial Statements

Table of Contents

AC Immune SA, Ecublens

Research and development expenditures

Given the stage of development of the Company’s products, all research expenditure is recognized as expense when incurred. Research and development expenditures include:

●

fees and costs related to regulatory filings and activities;

●

costs associated with preclinical and clinical activities;

●

employee-related expenses, including salaries and bonuses, benefits, and travel expenses; and

●

all other allocated expenses such as facilities and information technology (IT) costs.

For external research contracts, expenses include those associated with contract research organizations, or CROs, or contract manufacturing organizations, or CMOs. The invoicing from CROs or CMOs for services rendered does not always align with the timing of services performed. We accrue the cost of services rendered in connection with CRO or CMO activities based on our estimate of the “stage of completion” for such contracted services. We maintain regular communication with our CRO or CMO vendors to gauge the reasonableness of our estimates and accrue expenses as of the balance sheet date in the financial statements based on facts and circumstances known at the time.

Property, plant and equipment


IT equipment		3 years
Laboratory equipment		5 years
Leasehold improvements / furniture		5 years

Gains and losses on disposals are determined by comparing the disposal proceeds with the carrying amount and are included in the income statement.

Intangible asset

The Company reviews the in-process research and development (IPR&D) asset at least annually for impairment by assessing the fair value less costs to sell (recoverable amount) and comparing this to the carrying value of the asset. The Company has determined the IPR&D asset was not impaired as of December 31, 2025 and 2024, respectively.

Statutory Financial Statements

Table of Contents

AC Immune SA, Ecublens

The key assumptions used in the valuation model in accordance with an income approach to determine the recoverable amount include observable and unobservable key inputs as follows:

●

Anticipated research and development costs;

●

Anticipated costs of goods and sales and marketing expenditures;

●

Probability of achieving clinical and regulatory development milestones in accordance with certain industry benchmarks;

●

Target indication prevalence and incidence rates;

●

Anticipated market share;

●

General commercialization expectations such as anticipated pricing and uptake;

●

Expected patent life and market exclusivity periods; and

●

Other metrics such as the tax rate.

The Company’s valuation model calculates the risk-adjusted, net cash flows through the projected period of market exclusivity across target sales regions. The Company uses a discount rate of 17% (17% for 2023), based on the assumed cost of capital for the Company over the forecast period.

Intercompany equity investment

The Company commenced financial operations in the United States in 2021 via the opening of its fully-owned subsidiary, AC Immune USA, Inc. (“the Subsidiary”). The Subsidiary is located at 17 State Street Fl 40, New York, USA, and is registered and organized under the laws of Delaware, USA. The Company owns 100% of the Subsidiary, paying in less than USD 1 (CHF 1) for 100 shares of par value USD 0.01 of the Subsidiary’s shares.

Financial assets and liabilities

The Company’s financial assets and liabilities are comprised of receivables, cash and cash equivalents, short-term financial assets and trade payables.

Receivables

Receivables are non-derivative financial assets with fixed payments that are not quoted in an active market. They arise when the Company provides money, goods or services directly to a debtor with no intention of trading the receivable. They are included in current assets, except for those with maturities greater than 12 months after the balance sheet date, which are classified as long-term assets. Receivables are recognized at their billing value. An allowance for doubtful accounts is recorded for potential estimated losses when there is evidence of the debtor’s inability to make required payments and the Company assesses on a forward-looking basis the expected credit losses associated with these receivables held at amortized cost.

Short-term financial assets

Short-term financial assets are held with external financial institutions and comprise fixed-term deposits with maturities ranging from more than 3 until 12 months in duration.

Statutory Financial Statements

Table of Contents

AC Immune SA, Ecublens

Cash and cash equivalents

Cash and cash equivalents include deposits held with external financial institutions and cash on hand. All cash and cash equivalents are either in cash or in deposits with original duration of less than 3 months. The Company assesses at each period whether there is objective evidence that financial assets are impaired.

Trade payables

Trade payables are recognized initially at nominal amount, which represents cost incurred.

Significant shareholders

Principal shareholders who own more than 5 percent of the voting rights as of December 31:


	Shares owned			Shares owned
	2025			2024
Principal shareholders	Number	Percent		Number	Percent
5% Shareholders
BVF Inc.⁽¹⁾	19,822,436	20.0	%	19,522,436	19.7	%
dievini Hopp BioTech holding GmbH & Co KG⁽²⁾	16,316,742	16.4	%	16,316,742	16.5	%
Varuma AG⁽³⁾	11,999,999	12.1	%	11,999,999	12.1	%
Affiris⁽⁴⁾	6,428,100	6.5	%	6,428,100	6.5	%

(1)	Based on information set forth in a Schedule 13F filed with the SEC by BVF on February 17, 2026, these shares consist of 19,822,436 shares held of record by BVF Inc. The address of BVF Inc. is 44 Montgomery St., 40th Floor, San Francisco, California 94104.

(2)	Based on information set forth in a Schedule 13G/A filed with the SEC by dievini Hopp BioTech holding GmbH & Co KG (“dievini”) on February 10, 2023. These shares consist of 16,316,742 shares held by dievini.

DH-Capital GmbH & Co. KG (“DH-Capital”) and OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”) are collectively the holders of 100% of the limited partner interest in dievini and therefore, control the voting and dispositive decisions of dievini together and may be deemed to beneficially own the shares held by dievini. Dietmar Hopp, Oliver Hopp and Daniel Hopp are the ultimate controlling persons of dievini, DH-Capital and OH Beteiligungen, and control the voting and investment decisions of the ultimate parent company of dievini and therefore, may be deemed to beneficially own the shares held by dievini by virtue of their status as controlling persons of dievini.

The address of the principal business office of dievini and Dietmar Hopp is c/o dievini Hopp BioTech holding GmbH & Co. KG, Johann-Jakob-Astor Straße 57, 69190 Walldorf, Germany. The address of the principal business office of DH-Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG is Opelstraße 28, 68789 St. Leon-Rot, Germany. The address of the principal business office of Oliver Hopp is Johann-Jakob-Astor-Straße 59, 69190 Walldorf, Germany

(3)	Represents 11,999,999 shares held by Varuma AG set forth in a Schedule 13G/A filed with the SEC on February 12, 2019. The address for Varuma AG is Aeschenvorstadt 55, CH 4051 Basel, Switzerland. Rudolf Maag controls the voting and investment decisions of Varuma AG.

(4)	Based on information set forth in a Schedule 13G/A filed with the SEC by Affiris AG December 13, 2024, these shares consist of 6,428,100 shares held of record by Affiris AG. The address of Affiris AG is Karl-Farkas-Gasse 22, 1030 Vienna, Austria.

Statutory Financial Statements

Table of Contents

AC Immune SA, Ecublens

Operating lease liabilities

We have been a tenant at our current location in the EPFL Innovation Park in Ecublens/Lausanne since shortly after our inception in 2003. We lease our corporate, laboratory and other facilities under multiple operating leases that are month to month with no termination clause longer than a 12-month contractual notice period. Our lease agreements are structured such that we can exit these lease agreements without penalty provided we give the owner of our premises sufficient notice. As of December 31, 2025, the total minimum liability for the remaining term was CHF 1.4 million.

Provisions

During 2025, AC Immune incurred restructuring costs associated with planned initiatives to reduce our costs. The most significant restructuring costs are termination benefits provided to employees. In connection with developing a detailed formal plan for the restructuring, the Company established a provision for restructuring costs and, through execution of the plan and announcement of its main features to those affected by it, a valid expectation has been raised in those affected that the plan will be implemented. See Note 11 for full details on the expenses incurred and the liability remaining at December 31, 2025.

Critical judgments and accounting estimates

The preparation of financial statements in conformity with the Swiss Code of Obligations requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses.

The areas where AC Immune has had to make judgments, estimates and assumptions relate to (i) revenue recognition on option, collaboration and licensing agreements, (ii) clinical development accruals and (iii) IPR&D asset. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Information relating to items on Balance Sheets and Income Statements

3.	Property, plant and equipment


		As of December 31,
In CHF thousands		2025		2024
Furniture and fixtures		334		333
IT equipment		2,545		2,387
Lab equipment		10,935		10,536
Leasehold improvements		1,890		1,863
Total acquisition cost		15,704		15,119
Accumulated depreciation		(13,715)		(12,468)
Total property, plant and equipment		1,989		2,651

4.	Intangible assets


	As of December 31,
In CHF thousands	2025		2024
Intangible assets	50,416		50,416
Total intangible assets	50,416		50,416

Statutory Financial Statements

Table of Contents

AC Immune SA, Ecublens

5.	Long-term financial assets


	As of December 31,
In CHF thousands	2025		2024
Rental deposit (restricted cash)	582		412
Security deposit	3		3
Total long-term financial assets	585		415

6.	Cash and cash equivalents and short-term financial assets


	As of December 31,
In CHF thousands	2025		2024
Cash and cash equivalents	26,781		36,260
Short-term financial assets due in one year or less	64,617		129,214
Total cash and cash equivalents and short-term financial assets	91,398		165,474

Cash and cash equivalents by currency
CHF	21,815		20,798
EUR	3,632		7,308
USD	1,207		8,154
Other	127		—
Total cash and cash equivalents	26,781		36,260

Short-term financial assets by currency
CHF	37,068		95,006
EUR	17,384		18,705
USD	10,165		15,503
Total short-term financial assets	64,617		129,214

7.	Other current receivables


	As of December 31,
In CHF thousands	2025		2024
Other current receivables
- From third parties	928		1,056
- Intercompany	—		4
Total other current receivables	928		1,060

8.	Prepaid expenses


		As of December 31,
In CHF thousands		2025		2024
Prepaid expenses		3,972		4,301
Total prepaid expenses		3,972		4,301

Statutory Financial Statements

Table of Contents

AC Immune SA, Ecublens

9.	Accrued income


		As of December 31,
In CHF thousands		2025		2024
Accrued income		360		1,099
Total accrued income		360		1,099

10.	Trade payables and accrued expenses


		As of December 31,
In CHF thousands		2025		2024
Trade payables
- From third parties		2,063		2,658
- Intercompany		3		—
Total trade payables		2,066		2,658

Accrued payroll expenses		3,689		3,866
Accrued R&D costs		2,497		6,505
Restructuring Provision		291		—
Other accrued expenses		1,042		1,417
Total accrued expenses		7,520		11,788
Total trade payables and accrued expenses		9,586		14,446

As of December 31, 2025 and 2024 the Company held liabilities toward our pension insurance provider, amounting to nil and CHF 728 thousand, respectively.

11.	Restructuring expenses

On September 4, 2025, the Company announced that following a strategic review, the Company is sharpening its focused investment on its most important assets and implementing cost reduction measures accordingly. As a result of the initiatives announced in September 2025, the Company recorded CHF 2.1 million of restructuring expenses in the year ending December 31, 2025, consisting solely of CHF 2.1 million of termination benefits to be paid to the employees impacted by the restructuring. As of December 31, 2025, a provision of CHF 291 thousand remained to be paid in 2026.

12.	Deferred contract revenue


		As of December 31,
In CHF thousands		2025		2024
Short-term deferred contract revenue		83,706		85,056
Total short-term deferred contract revenue		83,706		85,056

Long-term deferred contract revenue		2,339		4,560
Total long-term deferred contract revenue		2,339		4,560

Statutory Financial Statements

Table of Contents

AC Immune SA, Ecublens

billion if all related milestones are achieved over the course of the agreement. Upon commercialization, AC Immune will be entitled to receive tiered mid-to-high teens percentages royalties on worldwide net sales.

For the year ended December 31, 2025, the Company recorded contract revenue CHF 3.6 million reflecting its efforts under this agreement.

As of December 31, 2024, the Company recorded CHF 89.6 million in deferred contract revenue related to the unsatisfied performance obligations under this agreement. The deferred contract revenue allocated to the license option is classified as short-term. The deferred contract revenue allocated to development, CMC, and regulatory activities will be recognized over the remaining performance period and classified as either current or non-current on the statutory balance sheets, based on the expected timing of satisfaction of the performance obligations.

13.	Share capital

As of December 31, 2025 and 2024, the issued share capital amounted to CHF 2,202,019 and CHF 2,198,645, respectively, and is composed of common shares of 110,100,925 and 109,932,248, respectively. The common shares have nominal values of CHF 0.02 per share. All shares have been fully paid.

In Q2 2024, the Company issued 5,700,000 common shares with a nominal value of CHF 0.02 to be held as treasury shares. As of December 31, 2024, the Company has CHF 475.6 million of reserves from capital contributions confirmed by the Swiss Federal Tax Administration.

On December 19, 2023, the Company announced that it had closed an underwritten offering of 14,300,000 common shares, resulting in gross proceeds of approximately USD 50.1 (CHF 43.8) million. Net underwriting fees and transaction costs totaled CHF 3.3 million for a net total of CHF 40.5 million. Transaction costs associated with these offerings and related to the issuance of new shares were charged directly against the reserves from capital contributions account thereby reducing the total shareholder equity reported.

14.	Treasury shares


		As of December 31,
		2025				2024
		Number		KCHF		Number		KCHF
Treasury shares – Tranche 1 (September 2020)		2,806,613		56		2,806,613		56
Treasury shares – Tranche 2 (May 2021)		2,393,160		48		2,393,160		48
Treasury shares – Tranche 3 (June 2024)		5,700,000		114		5,700,000		114
Total		10,899,773		218		10,899,773		218

Commencing in September 2020, the Company established an “at the market offering” (ATM) for the sale of up to USD 80.0 (CHF 64.0) million worth of our common shares from time to time by entering into an Open Market Sale Agreement (Sales Agreement) with Jefferies LLC (Jefferies). In Q2 2021 and Q2 2024, we filed a new registration statement on Form F-3 and entered into a new Sales Agreement in Q2 2021 and Q3 2024 to replace and extend the ATM program. To date, the Company has sold 2,179,434 common shares previously held as treasury shares pursuant to the Sales Agreement, raising USD 16.4 (CHF 14.9) million, net of underwriting fees and transaction costs.

As of December 31, 2024, the Company held in total 10,899,773 fully paid-in treasury shares as part of its ATM offerings. These shares were established via three tranches (one in September 2020, one in September 2021 and one in June 2024, respectively). Under present Swiss tax laws, repurchases of shares for the purposes of cancellation are treated as a partial liquidation and are subject to 35% Swiss withholding tax on the difference between the repurchase price and the nominal value of the shares except, since January 1, 2011, to the extent these are booked against the reserves from capital contributions confirmed by the Swiss Federal Tax Administration (apports de capital) if any. No partial liquidation treatment applies and no withholding tax is triggered if the shares are not repurchased for cancellation but held by the Company as treasury shares, provided the limitations imposed by corporate law are respected (the nominal

Statutory Financial Statements

Table of Contents

AC Immune SA, Ecublens

value of such shares does not exceed 10% of the outstanding share capital and the purchase price is covered by freely disposable equity). However, regarding the above-mentioned 10,899,773 treasury shares and given the specificities of the ATM offering, the Company sought and obtained a tax ruling for the two first tranches from the Swiss Federal Tax Administration confirming that their acquisition by the Company did not constitute a direct partial liquidation and therefore does not trigger withholding tax. Further, the Company has obtained a tax ruling from the concerned Cantonal Tax Authority at its place of incorporation, to obtain confirmation that the placement of these treasury shares related to the two first tranches for a subscription price superior to their nominal value will not trigger any corporate income tax for the Company.

As of December 31, 2024, 2,806,613 shares from the first tranche have not been sold and are still recorded as treasury shares. In addition, 2,393,160 fully paid in treasury shares issued as part of second tranche, and 5,700,000 fully paid in treasury shares issued as part of the third tranche for the ATM for future subscription (or, possibly, as part of a future share-dividend program, should the Company become profitable and have enough earnings carried forward to cover such distribution) have not been sold and are still recorded as treasury shares as of December 31, 2024. The shares linked to the two first tranches are covered by the above-mentioned tax rulings (i.e. their acquisition does not trigger any withholding tax and their placement will not trigger any corporate income tax). The Company sought confirmation from the Cantonal Tax Authority at its place of incorporation that the same previous tax ruling remains valid and covers the third tranche as well. Based on the cantonal confirmation the company will assess with its tax advisors whether a confirmation should also be obtained from the Federal Tax Authority.

15.

Revenue


		For the Year Ended
		December 31,
In CHF thousands		2025		2024
Revenue		3,977		28,568
Total revenue		3,977		28,568

16.	Operating expenses


		For the Year Ended
		December 31,
In CHF thousands		2025		2024
Salaries and related costs
- related to research and development		20,222		20,386
- related to general administrative		8,567		8,330
- related to restructuring		2,129		—
Total salaries and related cost		30,918		28,716

Research and development expenses
- related to research and development		30,748		37,260
Total research and development expenses		30,748		37,260

General and administrative expenses
- related to general and administrative		7,557		8,459
- related to offering costs		—		4
- related to intercompany transactions		17		73
Total general and administrative expenses		7,574		8,536

Depreciation of fixed assets		1,378		1,485

Total operating expenses		70,618		75,997

Statutory Financial Statements

Table of Contents

AC Immune SA, Ecublens

17.	Financial income and expenses


		For the Year Ended
		December 31,
In CHF thousands		2025		2024
Financial income
- interest income		1,865		3,196
Total financial income		1,865		3,196

Financial expenses
- bank fees		(15)		(17)
- foreign exchange loss		(2,804)		(1,598)
Total financial expenses		(2,819)		(1,615)

Total financial result, net		(954)		1,581

18.	Shareholders rights and equity awards

The following table presents information on the equity awards granted to executive officers, directors and employees in accordance with Article 959c, paragraph 2, number 11 Swiss Code of Obligations (CO) in 2025 and 2024:


		In 2025				In 2024
		Number		KCHF		Number		KCHF
Equity awards granted to executive officers and directors		1,531,966		2,997		964,614		3,571
Equity awards granted to employees		652,863		1,472		536,942		2,120
Total		2,184,829		4,469		1,501,556		5,691

Equity awards are comprised of share option grants and restricted share awards. The fair value of our share option grants is determined using the Black-Scholes-Merton Model and restricted share awards are valued using the market value of the common stock on the date of the award.

The table below presents beneficial ownership of executive officers and directors, including affiliated entities, if applicable, as of December 31, 2025:


				Number of equity
Beneficial ownership of executive officers and directors		Number of shares		awards
Andrea Pfeifer, Ph.D., Chief Executive Officer and Director		1,949,283		2,915,810
Anke Post, Chief Medical Officer		—		261,503
Christopher Roberts, Chief Financial Officer		45,818		266,820
Howard Donovan, Chief Human Resources Officer		—		243,354
Piergiorgio Donati, Chief Technical Operations Officer		4,500		377,836
Martin Zügel, M.D., Chair and Director		—		122,910
Monika Bütler, Ph.D., Vice Chair and Director		1,000		224,735
Renée Aguiar-Lucander, Director		—		109,928
Roy Twyman, M.D., Director		26,000		233,264
Carl June, M.D., Director		1,000		212,069

Statutory Financial Statements

Table of Contents

AC Immune SA, Ecublens

19.	Post balance sheet events

Management has evaluated subsequent events after the balance sheet date, through the issuance of these financial statements, for appropriate accounting and disclosures. The Company has determined that there were no other such events that warrant disclosure or recognition in these financial statements.

Statutory Financial Statements

Table of Contents

AC Immune SA, Ecublens


Accumulated losses carried forward

	As of December 31,
In CHF thousands	2025	2024
Accumulated losses at the beginning of the period	(356,846)	(310,998)
Loss for the year	(67,595)	(45,848)
Accumulated losses available to the Annual General Meeting	(424,441)	(356,846)


Motion of the Board of Directors on the proposed carry forward of the accumulated losses

	As of December 31,
	Motion of the	Resolution of
	Board of	the Annual
	Directors	General Meeting
In CHF thousands	2025	2024
Accumulated losses available to the Annual General Meeting	(424,441)	(356,846)
Carried forward	(424,441)	(356,846)

Statutory Financial Statements

Compensation Report in accordance with Article 734 para. 1 of the Swiss Code of Obligations (CO)

Contents

●

Report of the Statutory Auditor

●

Compensation of the Board of Directors

●

Compensation of the Members of the Executive Management

●

Equity Incentive Plans of the Board of Directors and the Members of the Executive Management

●

Mandates outside AC Immune SA

●

Compensation Philosophy, Principles and Governance

Report of the statutory auditor to the General Meeting of AC Immune SA, Ecublens

Opinion

We have audited the compensation report of AC Immune SA (the Company) for the year ended December 31, 2025. The audit was limited to the information pursuant to article 734a-734f of the Swiss Code of Obligations (CO) in the tables 1.c., 2.c., 3 and 4 and the information in sections 1.b. and 3 of the compensation report.

In our opinion, the information pursuant to article 734a-734f CO in the accompanying compensation report complies with Swiss law and the Company’s articles of incorporation.

Basis for opinion

We conducted our audit in accordance with Swiss law and Swiss Standards on Auditing (SA-CH). Our responsibilities under those provisions and standards are further described in the 'Auditor’s responsibilities for the audit of the compensation report' section of our report. We are independent of the Company in accordance with the provisions of Swiss law and the requirements of the Swiss audit profession, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

The Board of Directors is responsible for the other information. The other information comprises the information included in the annual report, but does not include the tables 1.c., 2.c., 3 and 4 and the information in sections 1.b. and 3 in the compensation report, the consolidated financial statements, the financial statements and our auditor’s reports thereon.

Our opinion on the compensation report does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the compensation report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the audited financial information in the compensation report or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Board of Directors’ responsibilities for the compensation report

The Board of Directors is responsible for the preparation of a compensation report in accordance with the provisions of Swiss law and the Company’s articles of incorporation, and for such internal control as the Board of Directors determines is necessary to enable the preparation of a compensation report that is free from material misstatement, whether due to fraud or error. It is also charged with structuring the remuneration principles and specifying the individual remuneration components.

Auditor’s responsibilities for the audit of the compensation report

Our objectives are to obtain reasonable assurance about whether the information pursuant to article 734a-734f CO is free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Swiss law and SA-CH will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this compensation report.

As part of an audit in accordance with Swiss law and SA-CH, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

●

Identify and assess the risks of material misstatement in the compensation report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

●	Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control.

●	Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made.

We also provide the Board of Directors or its relevant committee with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

PricewaterhouseCoopers SA

/s/ Alex Fuhrer	/s/ Thomas Kohler
Licensed audit expert	Licensed audit expert
Auditor in charge

Lausanne, March 13, 2026

This compensation report of AC Immune SA (the “Company”) has been prepared in accordance with the Swiss Code of Obligations (“CO”).

Compensation of the Board of Directors

2025 and 2024 Board Composition

Our Board of Directors is composed of six directors, including our Chief Executive Officer (“CEO”). Each director is elected for a renewable one-year term. The current members of our Board of Directors were appointed at the 2025 shareholders’ meeting held on 19 June 2025 (“2025 AGM”) to serve until the 2026 shareholders’ meeting planned for June 2026.


Name	Appointed to the Board of Directors	Board role	Audit and Finance Committee (AFC)	Compensation, Nomination and Governance Committee (CNC)
Andrea Pfeifer, Ph.D.	2016	Director – CEO
Douglas Williams, Ph.D.⁽¹⁾	2018	Chair	Member ⁽³⁾	Member
Werner Lanthaler, Ph.D.⁽¹⁾	2018	Director	Member ⁽⁴⁾
Roy Twyman, M.D.	2019	Director		Member
Carl June, M.D.	2020	Director
Monika Bütler, Ph.D.	2021	Vice Chair	Chair	Chair
Monica Shaw, M.D.⁽¹⁾	2021	Director	Member
Renée Aguiar-Lucander ⁽²⁾	2025	Director	Member
Martin Zügel, M.D. ⁽²⁾	2025	Chair	Member	Member

⁽¹⁾ Until 19 June 2025. Did not stand for reelection at AC Immune’s 2025 AGM.

⁽²⁾Newly appointed at the 2025 AGM on 19 June 2025.

⁽³⁾ Appointed from 9 February 2024 until 19 June 2025.

⁽⁴⁾ Until 2 February 2024.

Pursuant to the NASDAQ Marketplace Rule 5615(a)(3), the Company follows Swiss rules in lieu of the NASDAQ exchange listing rules for rules regarding the nominations committee, independent director oversight of executive officer compensation, majority independent board representation and the establishment of, or amendments to, equity-based compensation plans for employees. Swiss law does not require that a majority of our Board of Directors consists of independent directors. However, Roy Twyman, Carl June, Monika Bütler, Renée Aguiar-Lucander and Martin Zügel are all independent directors. Douglas Williams, Werner Lanthaler and Monica Shaw were deemed to be independent directors during their tenure as members of our Board of Directors. In making such determination, our Board of Directors considered the relationships that each non-employee director has with us and any other circumstances our Board of Directors deemed relevant in determining director independence, including the number of ordinary shares, if any that are beneficially owned by directors and their affiliated entities.

Compensation Structure

Board members are paid a fixed fee that depends on the function exercised. Board fees are determined in alignment with market practice. In addition to the fixed fee, board members are awarded equity instruments under the Company’s equity incentive plans as described within the section “Equity Incentive Plans” of this report. Annual fixed fees, excluding social security contributions are paid semi-annually, in Swiss Francs (“CHF”) as follows:


	from 2024 and from 2025 (CHFk)
	Chair	Member
Board of Directors⁽¹⁾	87	54⁽²⁾
Compensation, Nomination and Governance Committee	15	10
Audit and Finance Committee	15	10

⁽¹⁾Board member and CEO, Professor Andrea Pfeifer is unremunerated for her Board participation (see also the overview on Board compensation below).

⁽²⁾The role of Vice Chair was reintroduced in 2023 to take on responsibilities delegated by the Chair, and to deputize for the Chair during any absence. Vice Chair’s additional responsibilities are remunerated with an annual board fee of CHF 70k.

2025 and 2024 Board Compensation

In 2025 and 2024, the total compensation of the members of the Board of Directors consisted of board fees, social security contributions and compensation paid in the form of equity instruments as detailed below:

Year	Name	Gross Cash Compensation	FMV of Equity instruments granted⁽⁵⁾⁽⁶⁾	Total Annual Compensation⁽⁷⁾
		(CHFk)
2025	Douglas Williams, Ph.D.⁽¹⁾	56	-	56
2024	Douglas Williams, Ph.D.⁽¹⁾		106	85	191

2025	Andrea Pfeifer, Ph.D.⁽²⁾	-	-	-
2024	Andrea Pfeifer, Ph.D.⁽²⁾		-	-	-

2025	Werner Lanthaler, Ph.D.⁽¹⁾	29	-	29
2024	Werner Lanthaler, Ph.D.⁽¹⁾		58	70	128

2025	Roy Twyman, M.D.⁽⁴⁾	66	70	136
2024	Roy Twyman, M.D.⁽⁴⁾		64	70	134

2025	Carl June, M.D.	54	70	124
2024	Carl June, M.D.		54	70	124

2025	Monika Bütler Ph.D.	107	75	182
2024	Monika Bütler Ph.D.		104	75	179

2025	Monica Shaw M.D.⁽¹⁾	34	-	34
2024	Monica Shaw M.D.⁽¹⁾		68	70	138

2025	Renée Aguair-Lucander ⁽³⁾	34	140	174
2024	Renée Aguair-Lucander ⁽³⁾		-	-	-

2025	Martin Zügel M.D. ⁽³⁾	54	155	209
2024	Martin Zügel M.D. ⁽³⁾		-	-	-

	Total 2025	434	510	944
	Total 2024	454	440	894

⁽¹⁾ Board member until 19 June 2025. Did not stand for re-election at AC Immune’s 2025 AGM.

⁽²⁾Unremunerated for board participation; compensation is included in section 2c below.

⁽³⁾Newly appointed at the AGM 2025 on 19 June 2025.

⁽⁴⁾ In addition, Roy Twyman received CHF 35k and CHF 66k as compensation for consultancy services in 2025 and 2024, respectively.

⁽⁵⁾A mixture of Stock Options and Restricted Share Units (“RSUs”), as further described in Section 3 below, are granted. The fair value of RSUs are determined using a reasonable estimate of the market value of common shares on the award date. Stock options grants are valued using the Black-Scholes model and their exercise price is set using the market price at the grant date.

⁽⁶⁾ Fair market value (“FMV”) excludes Swiss social security contributions which become due when a beneficiary exercises or settles their equity award.

⁽⁷⁾AC Immune also paid contributions to the social security system, which amounted to CHF 25k and CHF 28k in 2025 and 2024, respectively.

d. Loans to Board Members, payments to Related Parties of Board Members and payments to former members of the Board of Directors in 2025 and 2024

During this period, the Company neither promised nor provided loans, nor had any loans outstanding to present or former members of Board of Directors. Except for anything disclosed in the table in Section 2(c), no payments to related parties of present or former members of the Board of Directors were made in 2025 and 2024.

In 2025 and 2024, consulting fees of CHF 20k and nil, respectively, were paid to a former member of the Board of Directors.

Compensation for Members of Executive Management

2025 and 2024 Executive Management Composition

The Executive Management for the years ended 31 December 2025 and 2024 was comprised of:

Name	Function	Appointment
Andrea Pfeifer, Ph.D.	Chief Executive Officer	2003
Jean-Fabien Monin ⁽¹⁾	Chief Administrative Officer	2009
Piergiorgio Donati	Chief Technical Operations Officer	2019
Howard Donovan ⁽⁵⁾	Chief Human Resources Officer	2022
Christopher Roberts⁽²⁾	Chief Financial Officer	2022
Nuno Mendonça M.D ⁽¹⁾	Chief Medical Officer	2023
Madiha Derouazi ⁽³⁾	Chief Scientific Officer	2024
Anke Post ⁽⁴⁾	Chief Medical Officer	2024

⁽¹⁾Until departure 31 December 2024.

⁽²⁾Formally appointed to Executive Management team with effect from 1 January 2024.

⁽³⁾ From appointment on 1 January 2024 until departure on 31 January 2025.

⁽⁴⁾ From appointment on 16 September 2024 until June 2025. She continues to receive compensation until end of June 2026.

⁽⁵⁾ From appointment on 1 July 2022 until end of November 2025. He continues to receive compensation until end of November 2026.

Executive Compensation Principles

Each Executive Management member receives remuneration of a base salary, car allowance, short-term incentive plan, social security benefits, and an equity incentive plan. These compensation principles are more fully described in the Compensation Philosophy, Principles and Governance section of this report.

2025 and 2024 Executive Compensation

The total Executive Management Compensation includes the CEO’s remuneration, which is individually disclosed. The Executive Management compensation for the years ending 31 December 2025 and 2024 are outlined below:

Year	Name	Cash Compensation	Other Compensation	Pension (employer)	Cash Bonus	Total⁽¹⁾	Equity FMV ^(2)(3)(4)
		(in CHFk)
2025	Andrea Pfeifer, Ph.D.	610	28	144	438	1,220	1,450
2024	Andrea Pfeifer, Ph.D.		578	28	126	536	1,268	1,450

2025	Total Executive Management Compensation	2’150	77	418	843	3,488	2,275
2024	Total Executive Management Compensation		2,773	103	476	1,304	4,656	2,498

⁽¹⁾AC Immune also paid the company-related portion of social security contributions for members of the Executive Management in line with applicable laws where the executives are employed. This was an aggregate amount of CHF 280k in 2025 and CHF 400k in 2024, which includes the employer cost of accident and loss of salary through illness insurance. Additional employer social charges, related to equity transactions, were for an amount of CHF 4k and 9k in the aggregate for Executive Management in 2025 and 2024, respectively.

⁽²⁾A mixture of Stock Options and RSUs were granted in 2025 and 2024. These awards are further described in Section 3 below. Stock Options and RSUs awarded in 2025 vest between 2025 to 2027. Stock Options and RSUs awarded in 2024 vest between 2024 to 2026. 2025 and 2024 RSUs granted to the CEO vest during a 12-month period. We estimate the fair value of RSUs using a reasonable estimate of the market value of the common shares on the date the award is granted. Stock option grants are valued using the Black-Scholes pricing model.

⁽³⁾Fair market value (FMV) excludes Swiss social security contributions which become due when an equity instrument is exercised or settled.

⁽⁴⁾ The 2025 and 2024 aggregate equity grants reflect unvested equity that was awarded, and subsequently forfeited by departing Executive Management members, with a grant value of CHF 275k for 2025 and CHF 633k for 2024.

Loans to Executive Management, payments to Related Parties of Executive Management and payments to former members of Executive Management in 2025 and 2024

During this period, the Company neither promised nor provided loans, nor had any loans outstanding to present or former members of Executive Management. Additionally, no payments to related parties of present or former members of the Executive Management were made in 2025 and 2024.

In 2025 and 2024, a former member of Executive Management received compensation for providing non-executive scientific advisor services, with a total amount of CHF 404k and CHF 451k, respectively. AC Immune also paid this former member of Executive Management the company-related portion of social security contributions in line with applicable laws where the executives are employed. This was an aggregate amount of CHF 35k in 2025 and CHF 47k in 2024, which includes the employer cost of accident and loss of salary through illness insurance.

Equity Incentive Plans of the Board of Directors and the Executive Management

Board of Directors and Executive Management Equity Incentive Plan Summary

The members of the Board of Directors and Executive Management held the following equity instruments, as outlined in the following two tables, as of 31 December 2025 and 2024:

Investments held by members of the Board of Directors ⁽¹⁾

Year	Name	Function	Number of Shares	Number of vested Stock Options ⁽³⁾	Number of unvested Stock Options - ⁽³⁾	Number of vested RSUs ⁽⁴⁾	Number of unvested RSUs ⁽⁴⁾
2025	Douglas Williams, Ph.D.⁽²⁾	Chair	-	-	-	-	-
2024	Douglas Williams, Ph.D.⁽²⁾	Chair			16,000	129,458	17,114	42,008	9,392

2025	Werner Lanthaler, Ph.D.⁽²⁾	Director	-	-	-	-
2024	Werner Lanthaler, Ph.D.⁽²⁾	Director			103,128	107,701	14,094	36,875	7,735

2025	Roy Twyman, M.D.	Director	26,000	139,977	43,299	32,704	17,284
2024	Roy Twyman, M.D.	Director			26,000	125,883	14,094	24,969	7,735

2025	Carl June, M.D.	Director	1,000	118,782	43,299	32,704	17,284
2024	Carl June, M.D.	Director			1,000	104,688	14,094	24,969	7,735

2025	Monika Bütler, Ph. D.	Vice Chair	1,000	125,438	46,392	34,386	18,519
2024	Monika Bütler, Ph. D.	Vice Chair			1,000	110,337	15,101	26,099	8,287

2025	Monica Shaw, M. D.⁽²⁾	Director	-	-	-	-	-
2024	Monica Shaw, M. D.⁽²⁾	Director			-	107,682	14,094	24,969	7,735

2025	Renée Aguiar-Lucander	Director	-	-	75,360	-	34,568
2024	Renée Aguiar-Lucander			-	-	-	-	-

2025	Martin Zügel M.D.	Chair	-	-	84,638	-	38,272
2024	Martin Zügel M.D.			-	-	-	-	-

	Total 2025		28,000	384,197	292,988	99,794	125,927
	Total 2024		147,128	685,749	88,591	179,889	48,619

⁽¹⁾Excluding Andrea Pfeifer, CEO, whose holdings are listed under Executive Management.

⁽²⁾Board member until 19 June 2025. Did not stand for re-election at AC Immune’s 2025 AGM. Since not a current Board member, no disclosures are made for 2025.

⁽³⁾Each stock option (SO) award, on vesting, entitles the recipient to purchase a quantity of the Company’s common shares, equivalent to the number of SOs exercised, with an exercise price of USD 1.84 for the 2025 option grants and USD 4.23 for 2024 option grants. Stock options (SOs) awarded in 2025 fully vest in 2026, and those awarded in 2024 fully vested in 2025.

⁽⁴⁾Each RSU granted entitles the Grantee to an equivalent number of the Company’s common shares. RSUs awarded in 2025 fully vest in 2026, and those awarded in 2024 fully vested in 2025. The settlement and delivery of shares occurs upon payment of the nominal value of each vested RSU.

Investments held by members of Executive Management	Name	Function	Number of Shares	Number of vested Stock Options ⁽⁵⁾	Number of unvested Stock Options	Number of vested RSUs ⁽⁶⁾	Number of unvested RSUs
2025	Andrea Pfeifer, Ph.D.	Chief Executive Officer	1,963,283	1,577,134	-	1,338,676	-
2024	Andrea Pfeifer, Ph.D.	Chief Executive Officer			2,146,071	1,306,292	270,842	629,593	114,821

2025	Jean-Fabien Monin ⁽¹⁾	Chief Administrative Officer	-	-	-	-	-
2024	Jean-Fabien Monin ⁽¹⁾	Chief Administrative Officer			311,950	159,753	-	10,345	-

2025	Piergiorgio Donati	Chief Technical Operations Officer	4,500	239,180	50,229	61,806	26,621
2024	Piergiorgio Donati	Chief Technical Operations Officer			4,500	180,010	47,861	33,932	21,708

2025	Nuno Mendonca ⁽¹⁾	Chief Medical Officer	-	-	-	-	-
2024	Nuno Mendonca ⁽¹⁾	Chief Medical Officer			-	54,459	-	27,111	-

2025	Madiha Derouazi ⁽²⁾	Chief Scientific Officer	-	-	-	-	-
2024	Madiha Derouazi ⁽²⁾	Chief Scientific Officer			6,349	24,540	49,080	6,349	25,397

2025	Anke Post ⁽³⁾	Chief Medical Officer	-	-	-	-	-
2024	Anke Post ⁽³⁾	Chief Medical Officer			-	3,645	29,168	1,828	14,630

2025	Howard Donovan ⁽⁴⁾	Chief Human Resources Officer	-	-	-	-	-
2024	Howard Donovan ⁽⁴⁾	Chief Human Resources Officer			-	72,396	44,378	34.096	21,740

2025	Christopher Roberts	Chief Financial Officer	45,818	123,704	81,745	19,059	42,312
2024	Christopher Roberts	Chief Financial Officer			20,135	59,280	53,861	9,930	27,944

2025	Total 2025		2,013,601	1,940,018	131,974	1,419,541	68,933
2024	Total 2024		2,489,005	1,860,375	495,190	753,184	226,240

⁽¹⁾Departed on 31 December 2024. Since not a current member of Executive Management, no disclosures are made for 2025.

⁽²⁾From appointment on 1 January 2024 until departure on 31 January 2025. Since not a current employee or member of Executive Management, no disclosures are made for 2025.

⁽³⁾ From appointment 16 September 2024 until June 2025. Since not a current member of Executive Management, no disclosures are made for 2025.

⁽⁴⁾ Until end of November 2025. Since not a current member of Executive Management, no disclosures are made for 2025.

⁽⁵⁾On vesting, each stock option (SO) entitles the recipient to purchase the Company’s common shares, equivalent to the number of SOs exercised, with the exercise price being the market price at grant date, which was USD 2.91 for 2025, and between USD 3.39 and 3.99 for 2024.

⁽⁶⁾Each RSU entitles the recipient to an equivalent number of the Company’s common shares. 2025 and 2024 RSUs granted to the CEO vest during a 12-month period. The settlement and delivery of shares occurs upon payment of the nominal value of each vested RSU.

Compensation of Current and Former Members of the Board and Executive Management

In connection with RSUs settled and options exercised in 2025 and 2024 by current and former members of the Board and Executive Management, AC Immune settles social security contributions, in accordance with applicable laws, on the gain resulting from the difference in exercise price and fair value of the shares at the time of the exercise. For former Board and Executive Management members, AC Immune paid CHF 4k and 11k in 2025 and 2024, respectively. For current Board and Executive Management members, AC Immune paid CHF 4k and CHF 9k in 2025 and 2024, respectively.

Mandates outside of AC Immune SA

According to article 37 and 38 of the Articles of Association (Corporate Governance | AC Immune SA), limitations apply to mandates outside AC Immune SA for Board Members and Executive Management members. The following external mandates as of 31 December 2025 and 31 December 2024, (unless otherwise indicated) are subject to these limitations and are therefore presented in the Compensation Report.

- Member of the Board of Directors		- CEO
Board Members
Current Members
Martin Zügel M.D. Grünenthal GmbH - Member of the Board of Directors - Chair of the Audit Committee AMW GmbH - Chair of the Supervisory Board MESI Ltd - Chair of the Supervisory Board		Renée Aguiar-Lucander Hansa Biopharma AB - CEO Inventiva Pharma - Member of the Board of Directors SwedenBio - Member of the Board of Directors
Monika Bütler, Ph. D. Swiss Life Holding Ltd⁽¹⁾ - Member of the Board of Directors - Member of the Audit Committee - Member of the Compensation Committee⁽¹⁰⁾ Swiss Life Ltd - Member of the Board of Directors - Member of the Audit Committee - Member of the Compensation Committee⁽¹⁰⁾ Schindler Holding AG⁽¹⁾ - Member of the Board of Directors - Member of the Audit Committee - Chair of the Compensation Committee⁽¹¹⁾ Huber+Suhner Ltd⁽¹⁾ - Member of the Board of Directors - Chair of the Nomination and Compensation Committee Gebert Rüf Foundation - Vice Chair Max Schmidheiny Foundation - Member of the Board of Trustees Manufactura Tessanda Val Müstair Foundation - Member of the Board of Trustees⁽⁸⁾ Swiss Management Association⁽¹²⁾ - Member of the Executive Board		Roy Twyman, M.D. Amron Neuroscience, LLC - CEO and Founder NeuroVision Imaging, Inc. - Member of the Board of Directors
Carl June Jupiter Bioventures⁽¹³⁾ - Member of the Board of Directors

Former Members
Douglas Williams, Ph.D. ⁽⁹⁾ Sana Biotechnology, Inc⁽¹⁾⁽²⁾ - Head of Research and Development Climb Bio, Inc.⁽³⁾ - Chair of the Board of Directors TriArm Therapeutics⁽³⁾ - Member of the Board of Directors Stablix, Inc. - Member of the Board of Directors		Werner Lanthaler, Ph.D.⁽⁹⁾ Evotec AG⁽¹⁾⁽⁴⁾ - Chief Executive Officer WLAN Holding AG - Managing Director Proxygen GmbH⁽⁵⁾ - Chair of the Board of Directors HAL Allergy B.V.⁽⁶⁾ - Chair of the Supervisory Board Soravia GmbH - Member of the Board of Directors Cerabyte GmbH⁽⁷⁾ - Member of the Board of Directors
⁽¹⁾ Listed company ⁽²⁾ Until April 2024 ⁽³⁾ From November 2024 ⁽⁴⁾ Until January 2024 ⁽⁵⁾ From June 2024 ⁽⁶⁾ From December 2024 ⁽⁷⁾ From May 2024 ⁽⁸⁾ From July 2024 ⁽⁹⁾ Tracked until departure from AC Immune’s board on 19 June 2025 ⁽¹⁰⁾ From May 2025 ⁽¹¹⁾ From March 2025, before Member of the Compensation Committee ⁽¹²⁾ Until March 2025 ⁽¹³⁾ From September 2025
Executive Management Members
Andrea Pfeifer, Ph.D. BioMedInvest AG II (in Liquidation) - Member of the Board of Directors AB2 Bio AG - Chair of the Board of Directors Symrise AG⁽¹⁾ - Member of the Supervisory Board E.M.S. Electro Medical Systems S.A. - Member of the Board of Directors		Christopher Roberts Msizi Africa - Trustee and Treasurer

Compensation Philosophy, Principles and Governance

AC Immune SA is a clinical-stage biopharmaceutical company leveraging our proprietary technology platforms to discover, design and develop novel proprietary medicines and diagnostics for prevention and treatment of neuro degenerative diseases (NDD) associated with protein misfolding. Misfolded proteins are generally recognized as the leading cause of NDD, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), with common mechanisms and drug targets, such as amyloid beta (Abeta), Tau, alpha-synuclein (a-syn) and TDP43, as well as downstream pathways such as chronic neuroinflammation triggered by aggregates of these misfolded proteins. Our corporate strategy is founded upon multiple pillars including a) Active Immunotherapies that target (i) Abeta and (ii) phosphorylated Tau to treat and ultimately prevent Alzheimer’s disease, and (iii) a-syn for Parkinson’s disease; and b) Intracellular Targeting to address these and other NDD indications using small molecules. We use our proprietary platform technologies, including SupraAntigen® (conformation-specific

biologics including Active Immunotherapies) and Morphomer® (conformation-specific small molecules), to discover, design and develop novel medicines and diagnostics for targeted applications against NDD.

AC Immune's compensation philosophy is intended to attract, motivate, and retain the best talent to achieve the Company’s strategic goals and deliverables. We ensure an equitable and competitive total compensation package. The Board believes that through combining short and long-term incentives, we align the interests of the members of the Board and Executive Management with the interests of the Company and its shareholders. Incentive compensation elements are focused on rewarding outstanding and sustainable results, as well as the demonstration of exceptional leadership, and high-quality governance standards.

In 2024 and 2023, the Company engaged a prominent remuneration expert advisory practice to analyse the compensation levels and structure for the members of the Board and Executive Management. The analysis included compensation data of comparable biopharmaceutical organisations, including companies based in Europe and the US. The Board of Directors concluded that compensation adjustments were appropriate for AC Immune to remain a competitive employer of high-quality executive, as well as board talent.

Method of Determining Compensation

The Role and Powers of the Compensation, Nomination and Governance Committee (“CNC”)

The CNC consists of three members, who are appointed at the Annual General Meeting. In the case of vacancies during the term of office, the Board of Director’s may appoint substitutes from amongst its members. The committee enacts its own charter, with certain duties described in Articles 28, 32 - 41 of the Articles of Association of AC Immune.

Compensation Guidelines:

The CNC recommends compensation guidelines for the members of the Board of Directors, the CEO, and the Executive Management, and submits these recommendations to the Board of Directors for approval.

The CNC provides an overall package for near- and long-term compensation, including variable compensation, which;

-	Is intended to attract, motivate, and retain talented people with the necessary competencies;

-	Is consistent with market conditions, and in the case of variable compensation, consistent with the Company’s and individual’s performance, and;

-	Aligns the interests of the Board of Directors members and the Executive Management with the Company's interests. The CNC also periodically reviews the compensation policies for employees who are outside the Executive Management.

The CNC meets at least four times per year and informs the Board of Directors of its recommendations and decisions after each meeting.

Approval of Compensation during the Annual General Meeting (AGM)

Swiss law requires a binding approval of the maximum compensation for the Board and the Executive Management. Under the current system, approved by the shareholders on 25 June 2021 and effective from the annual shareholder meeting held on 24 June 2022, shareholders approve annually and separately the proposals of the Board of Directors in relation to the maximum aggregate amount of:

-	The compensation of the Board of Directors for the period from the AGM to the next AGM;

-	Compensation of the Executive Management for the following financial year.

This annual Compensation Report is subject to a non-binding, advisory vote at the upcoming AGM.

If the AGM withholds approval for a respective motion by the Board of Directors, the Board of Directors may either submit a new motion at the same meeting or submit a new motion to either an Extraordinary General Meeting (EGM) or at the next AGM for approval. The Company may, subject to the approval by the AGM, remunerate within the framework of the maximum total remuneration.

Compensation of the Board of Directors

The CNC reviews and proposes to the Board of Directors the resolution to be submitted to the AGM for the maximum aggregate Board of Director remuneration. The CNC also requests Board of Director approval of individual compensation for members of the Board of Directors.

Annual compensation for members of the Board typically consists of cash compensation and an equity grant.

Additionally, the Company pays any employer social security contributions due on these amounts. To avoid a short-term corporate goal focus, board members do not receive variable compensation. Furthermore, they do not participate in the Company’s pension plan. Please see the tables on Page 3 for additional information.

Compensation of the Executive Management

The CNC evaluates the annual performance of the CEO and Executive Management team members and submits the evaluation to the Board of Directors for review and approval, without the CEO or Executive Management team members being present.

Subject to and within the bounds of the maximum compensation approved by the Annual Shareholders' Meeting, the CNC reviews and recommends for approval by the Board of Directors the annual base salary, incentive compensation (bonus) and equity compensation of the CEO, and after consultation with the CEO, of the Executive Management, as well as the aggregate compensation for the CEO and the Executive Management team. The CNC also requests approval by the Board of Directors regarding the determination of the compensation related incentive targets for the Executive Management team and requests Board of Director approval of individual compensation packages to be paid to members of the Executive Management.

2025 and 2024 Elements of Compensation

Base Salary

Base salaries are competitive to attract, motivate, and retain talented leaders with the necessary expertise, experience, and leadership profile. Base salary is based on the scope of the role and market assessment as well as the jobholder’s experience and skills. Fixed compensation for Executive Management team members includes base salary, car allowance and payments to the pension fund by the Company. Base salaries are assessed annually by the CNC, considering individual performance and the external remuneration assessment.

Bonus Plan

The CNC proposes to the Board of Directors an incentive bonus plan providing variable remuneration of the members of the Executive Management based on the achievement of the Company’s corporate goals, as well as individual contribution. The CNC reviews and approves any necessary bonus plan changes that are proposed

by the CEO. The CNC reviews and approves any employment contracts, separation agreements, or other agreements that the Company plans to enter into with any present, future, or former members of Executive Management, ensuring that key terms of contracts are submitted for the approval of the Board of Directors and function within maximum compensation limits approved during the Annual Shareholders' Meeting.

The annual cash bonus for 2025 and 2024 was based on the achievement of Company and individual goals. The target bonus for 2025 and 2024 (i.e., cash bonus to be paid if 100% of corporate and individual objectives are met) is determined individually for each member of the Executive Management as a fixed amount, ranging from 27% to 70% of their base salary for 2025, (median 38%) and 27% to 69% for 2024 (median 38%). According to the external benchmarking, target bonuses for most members of Executive Management continue to be in the low range of the peer group. The 2025 and 2024 corporate goals included: (i) fulfilment of various R&D milestones for several preclinical and clinical programs; (ii) establishing business development and financing opportunities for specific preclinical and clinical programs.

The weightings of individual goals are defined for each Executive Management member and vary depending on the position. In principle, more senior leadership positions place a greater weight on the achievement of company rather than individual goals. The Board determined that the actual target achievement of the 2025 and 2024 corporate goals was 103.0% and 103.6%, respectively.

Pension Plan and Social Charges

Pension Plan

The Company arranges for all employees, including its Executive Management team, to be affiliated with a pension plan organized by a legally independent pension institution. In addition to retirement savings, pension plan benefits include death or long-term disability risk benefits. A percentage of salary, adjusted for the age of the employee, is paid as contributions to the plan, and for 2025 was split on average 53% (53% in 2024) contributed by the employer and 47% (47% in 2024) by the employee. Pension plans are governed by the Swiss Law on Occupational Retirement, Survivors and Disability Pension Plans (BVG), under which contributions are made to a separately administered fund, which is governed by a trustee board that is responsible for administering plan rules and defining the investment strategy.

Social Security Contributions

The Company pays old age and survivors’ insurance (AHV), Disability insurance (IV), and Income replacement scheme (EO) as required by Swiss Federal law.

Equity Incentive Plans

2016 Option and Incentive Plans (Current Plan)

The 2016 Option and Incentive Plan as amended and restated as of October 7, 2019 (the “2016 Plan”) was established for the Executive Management, employees, non-employee directors and certain consultants of AC Immune SA. In June 2019, the Board authorized, and the shareholders approved, an increase in the maximum number of shares reserved for issuance under the 2016 Plan. In October 2019, the Board authorized a second amendment and restatement to the 2016 Plan to align certain elements with Swiss statutory requirements that had no financial impact for the Company in 2019. The 2016 Plan provides for various award types, including stock options, restricted share awards, RSUs, unrestricted share awards, and performance-based awards. Vesting and performance-based conditions vary by grant and are determined by the CNC (“the plan

administrator”), or the Chief Executive Officer under specified delegation limitations granted by the Board of Directors. The “Exercise Price” of Option awards are determined at the time of grant by the plan administrator and are not less than 100% of the fair market value at the grant date. Awards have an “Option Term” that may not exceed 10 years. 2025 and 2024 awards that were granted to members of the Executive Management team and Board of Directors are disclosed in Section 3 of this report. According to external benchmarking, equity awards continued to be in the lower range compared to the peer group.

Board Members and Executive Management equity

For the fiscal years ending December 31, 2025, and 2024, we granted Board members and Executive Management an aggregate grant of Options for the right to acquire 631,450 and 406,680 shares, respectively at an exercise price ranging from USD 1.84 to USD 2.91 per share in 2025, and from USD 3.39 to USD 4.23 per share in 2024. In 2025, we also granted RSUs for the right to 900,516 shares, with a market price of CHF 1.62 to CHF 2.44, and in 2024, we also granted RSUs for the right to 557,934 shares, with a market price of CHF 3.19 to CHF 4.20.

Options and RSUs that are granted annually to board members vest at the end of a one-year period. One time Option and RSU grants that are made to newly elected board members vest in tranches during a 3 year period. RSU grants to the CEO vest during a 12 month period, while Options and RSU grants to Executive Management vest in equal tranches quarterly over a three-year period.

Employment Agreements

The Executive Management team members are employed with employment agreements that have an unlimited duration with a notice period of twelve months for the Chief Executive Officer, Chief Technical Operations Officer, and Chief Financial Officer. Executive Management team members who leave AC Immune have no contractual entitlement to termination payments, although they retain vested portions of all equity grants.

Source: View Original Filing on SEC EDGAR

FAQ

How did AC Immune (ACIU) perform financially in 2025?

AC Immune generated CHF 3.6 million in 2025 contract revenue, down from CHF 27.3 million in 2024. The company reported a net loss of CHF 70.4 million versus CHF 50.9 million the prior year, with basic and diluted loss per share of CHF 0.70.

What is AC Immune’s cash position and liquidity at year-end 2025?

At December 31, 2025, AC Immune held CHF 26.8 million in cash and cash equivalents and CHF 64.6 million in short-term financial assets. Management concluded it can meet obligations for at least 12 months and prepared the financial statements on a going-concern basis, while acknowledging typical clinical-stage funding risks.

What are the key AC Immune (ACIU) clinical milestones expected in 2026?

AC Immune expects several 2026 milestones: final Part 1 data from the ACI-7104 VacSYn Phase 2 Parkinson’s trial in H2 2026, ABATE Phase 2 ACI-24 interim results in the AD3 cohort in H1 2026, Phase 1 results for ACI-19764 in H2 2026, and Morphomer Tau and α‑synuclein lead declarations in H1 2026.

What did AC Immune report about ACI-7104 in Parkinson’s disease?

AC Immune highlighted “exceptional interim data” from the VacSYn Phase 2 trial of ACI-7104, its wholly owned anti‑α‑synuclein active immunotherapy. Management stated that evidence suggests ACI-7104 appears to slow progression in early Parkinson’s disease, supporting the concept of disease‑modifying active immunotherapies.

What restructuring actions did AC Immune take in 2025?

Following a strategic review announced in September 2025, AC Immune implemented cost-reduction measures aligned with a sharpened pipeline focus. It recorded CHF 0.5 million of net restructuring expenses, including CHF 2.1 million in termination benefits and a non‑cash CHF 1.8 million curtailment gain on its defined benefit pension plan.

What is the large intangible asset on AC Immune’s balance sheet?

AC Immune carries a CHF 50.4 million acquired in‑process research and development (IPR&D) asset, a clinically validated active immunotherapy candidate for Parkinson’s disease. The asset is not yet amortized, is tested annually for impairment under IAS 36, and was assessed as not impaired at December 31, 2025.

Filing Exhibits & Attachments

4 documents

AC Immune (NASDAQ: ACIU) posts 2025 loss but flags key 2026 trial milestones

Rhea-AI Filing Summary

Positive

Negative

Insights

FAQ

How did AC Immune (ACIU) perform financially in 2025?

What is AC Immune’s cash position and liquidity at year-end 2025?

What are the key AC Immune (ACIU) clinical milestones expected in 2026?

What did AC Immune report about ACI-7104 in Parkinson’s disease?

What restructuring actions did AC Immune take in 2025?

What is the large intangible asset on AC Immune’s balance sheet?

Filing Exhibits & Attachments

Press Releases

NASDAQ:ACIU

ACIU Rankings

ACIU Latest News

ACIU Latest SEC Filings

ACIU Stock Data

Trending News

AC Immune (NASDAQ: ACIU) posts 2025 loss but flags key 2026 trial milestones

Rhea-AI Filing Summary

Positive

Negative

Insights

Biotech equity analyst neutral

FAQ

How did AC Immune (ACIU) perform financially in 2025?

What is AC Immune’s cash position and liquidity at year-end 2025?

What are the key AC Immune (ACIU) clinical milestones expected in 2026?

What did AC Immune report about ACI-7104 in Parkinson’s disease?

What restructuring actions did AC Immune take in 2025?

What is the large intangible asset on AC Immune’s balance sheet?

Filing Exhibits & Attachments

Press Releases

NASDAQ:ACIU

ACIU Rankings

ACIU Latest News

ACIU Latest SEC Filings

ACIU Stock Data